<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-06296R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004254</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Neuroscience</subject><subject>Genetics and Genomics/Animal Genetics</subject><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Neuroscience/Neurobiology of Disease and Regeneration</subject><subject>Pathology/Neuropathology</subject></subj-group></article-categories><title-group><article-title>IGFBP3 Colocalizes with and Regulates Hypocretin (Orexin)</article-title><alt-title alt-title-type="running-head">IGFBP3 Regulates Hypocretin</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Makoto</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Krister S.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shengwen</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tanaka</surname><given-names>Susumu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ling</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Salehi</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hesla</surname><given-names>Per Egil</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Maehlen</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gaus</surname><given-names>Stephanie E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yanagisawa</surname><given-names>Masashi</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Sakurai</surname><given-names>Takeshi</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Taheri</surname><given-names>Shahrad</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tsuchiya</surname><given-names>Kuniaki</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref></contrib><contrib contrib-type="author"><name><surname>Honda</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mignot</surname><given-names>Emmanuel</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff10"><sup>10</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Sleep Disorder Research Project, Tokyo Institute of Psychiatry, Setagaya, Tokyo, Japan</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Center for Narcolepsy, Stanford University, Palo Alto, California, United States of America</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of Neurology, Stanford University, Palo Alto, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Pathology, Oslo University, Oslo, Norway</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Molecular Genetics Department, University of Texas, Dallas, Texas, United States of America</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Department of Molecular Neuroscience and Integrative Physiology, Kanazawa University, Kanazawa, Japan</addr-line></aff><aff id="aff7"><label>7</label><addr-line>Laboratories for Integrative Neurosciences and Endocrinology, Bristol University, Bristol, United Kingdom</addr-line></aff><aff id="aff8"><label>8</label><addr-line>Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan</addr-line></aff><aff id="aff9"><label>9</label><addr-line>Japan Somnology Center, Neuropsychiatric Institute, Tokyo, Japan</addr-line></aff><aff id="aff10"><label>10</label><addr-line>Howard Hughes Medical Institute, Stanford University, Palo Alto, California, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rubinsztein</surname><given-names>David C.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">University of Cambridge, United Kingdom</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>honda@prit.go.jp</email> (MH); <email>mignot@stanford.edu</email> (EM)</corresp><fn fn-type="con"><p>Conceived and designed the experiments: MH EM. Performed the experiments: MH KSE SZ ST LL SEG ST KT. Analyzed the data: MH KSE ST LL SEG KT YH EM. Contributed reagents/materials/analysis tools: MH AS PEH JM MY TS YH EM. Wrote the paper: MH KSE SZ EM.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>22</day><month>1</month><year>2009</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>e4254</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2008</year></date></history><copyright-statement>Honda et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p>The sleep disorder narcolepsy is caused by a vast reduction in neurons producing the hypocretin (orexin) neuropeptides. Based on the tight association with HLA, narcolepsy is believed to result from an autoimmune attack, but the cause of hypocretin cell loss is still unknown. We performed gene expression profiling in the hypothalamus to identify novel genes dysregulated in narcolepsy, as these may be the target of autoimmune attack or modulate hypocretin gene expression.</p></sec><sec><title>Methodology/Principal Findings</title><p>We used microarrays to compare the transcriptome in the posterior hypothalamus of (1) narcoleptic versus control postmortem human brains and (2) transgenic mice lacking hypocretin neurons versus wild type mice. Hypocretin was the most downregulated gene in human narcolepsy brains. Among many additional candidates, only one, insulin-like growth factor binding protein 3 (IGFBP3), was downregulated in both human and mouse models and co-expressed in hypocretin neurons. Functional analysis indicated decreased hypocretin messenger RNA and peptide content, and increased sleep in transgenic mice overexpressing human IGFBP3, an effect possibly mediated through decreased hypocretin promotor activity in the presence of excessive IGFBP3. Although we found no IGFBP3 autoantibodies nor a genetic association with IGFBP3 polymorphisms in human narcolepsy, we found that an IGFBP3 polymorphism known to increase serum IGFBP3 levels was associated with lower CSF hypocretin-1 in normal individuals.</p></sec><sec><title>Conclusions/Significance</title><p>Comparison of the transcriptome in narcolepsy and narcolepsy model mouse brains revealed a novel dysregulated gene which colocalized in hypocretin cells. Functional analysis indicated that the identified IGFBP3 is a new regulator of hypocretin cell physiology that may be involved not only in the pathophysiology of narcolepsy, but also in the regulation of sleep in normal individuals, most notably during adolescence. Further studies are required to address the hypothesis that excessive IGFBP3 expression may initiate hypocretin cell death and cause narcolepsy.</p></sec></abstract><counts><page-count count="14"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Narcolepsy-cataplexy is a common sleep disorder affecting 0.02&#x02013;0.16&#x00025; of the general population in the United States, Europe and Asia. Disease onset may be insidious or abrupt, typically occurring around adolescence, and is characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone triggered by emotions) and other manifestations of abnormal Rapid Eye Movement (REM) sleep.</p><p>Narcolepsy has characteristic biological markers including Human Leukocyte Antigen (HLA) association and dysfunction of hypocretin (also called orexin) neurotransmission. Almost all patients with narcolepsy-cataplexy share a common HLA allele, <italic>DQB1&#x0002a;0602</italic><xref ref-type="bibr" rid="pone.0004254-Mignot1">&#x0005b;1&#x0005d;</xref> suggesting an autoimmune basis for the disorder. Over 90&#x00025; of narcolepsy-cataplexy cases are associated with a dramatic decrease in hypocretin-1 (HCRT1) in the cerebrospinal fluid <xref ref-type="bibr" rid="pone.0004254-Mignot2">&#x0005b;2&#x0005d;</xref>.</p><p>Hypocretin-1 is a neuropeptide produced by 50,000&#x02013;70,000 hypothalamic neurons in the human brain. The HCRT peptides are derived from a precursor, preprohypocretin, which is cleaved into two homologous peptides HCRT1 and HCRT2 <xref ref-type="bibr" rid="pone.0004254-Sakurai1">&#x0005b;3&#x0005d;</xref>. These act on target sites through two receptors, HCRT receptor-1 and HCRT receptor-2. Deficient HCRT neurotransmission is sufficient to produce narcolepsy, as animal models with dysregulated HCRT transmission exhibit a narcolepsy-like phenotype <xref ref-type="bibr" rid="pone.0004254-Chemelli1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004254-Lin1">&#x0005b;5&#x0005d;</xref>. Of notable interest is a transgenic mouse model where the <italic>HCRT</italic> promoter drives a form of ataxin-3 containing a large polyglutamine repeat, resulting in HCRT cell death and a narcolepsy-like phenotype at 2&#x02013;3 weeks of age <xref ref-type="bibr" rid="pone.0004254-Hara1">&#x0005b;6&#x0005d;</xref>.</p><p>Human neuropathological studies have extended on these results. <italic>In situ</italic> hybridization (ISH) studies have shown disappearance of <italic>HCRT</italic> mRNA in the perifornical area of narcoleptic brains. Furthermore, the concentrations of HCRT1 and HCRT2 in the cortex and pons, two areas with HCRT projections, are dramatically decreased <xref ref-type="bibr" rid="pone.0004254-Peyron1">&#x0005b;7&#x0005d;</xref>. Immunohistochemical studies also revealed more than 90&#x00025; decrease in HCRT cell counts in the hypothalamus of narcoleptic subjects <xref ref-type="bibr" rid="pone.0004254-Thannickal1">&#x0005b;8&#x0005d;</xref>. The loss of HCRT signal is most likely not a simple failure in producing hypocretin peptides alone. Hypocretin cells contain prodynorphin (PDYN) and neuronal pentraxin II (NPTX2; Neuronal Activity-Regulated Pentraxin) <xref ref-type="bibr" rid="pone.0004254-Chou1">&#x0005b;9&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004254-Reti1">&#x0005b;10&#x0005d;</xref>, and studies have shown that these two proteins are missing in the perifornical area, but not in other regions, of narcoleptic brains <xref ref-type="bibr" rid="pone.0004254-Blouin1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004254-Crocker1">&#x0005b;12&#x0005d;</xref>. This could imply that HCRT producing cells are quiescent and do not produce HCRT, PDYN and NPTX2 or, more likely, that these cells are missing entirely. Some authors have noted residual gliosis in the perifornical region <xref ref-type="bibr" rid="pone.0004254-Thannickal2">&#x0005b;13&#x0005d;</xref>, which combined with the strong HLA association, favors the hypothesis of autoimmune mediated destruction of HCRT neurons. However, most attempts to prove the autoimmune hypothesis, for example through the detection of HCRT-cell specific autoantibodies, have been unsuccessful <xref ref-type="bibr" rid="pone.0004254-Scammell1">&#x0005b;14&#x0005d;</xref>.</p><p>A deeper understanding of HCRT cell physiology is required, including the identification of genes and proteins that may be the target of an autoimmune attack or may modulate hypocretin expression/metabolism to make this cell population more susceptible to potential apoptosis. In this study, we have used postmortem human brain samples to compare the transcriptome of narcoleptic versus control subjects, with confirmation in animal models of narcolepsy. Our primary goal was to identify other genes and associated proteins that may be dysregulated in the posterior hypothalamus of narcoleptic patients, potentially expressed in HCRT neurons, as such genes are likely to be novel narcolepsy susceptibility genes.</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>Identification of brain region specific transcripts</title><p>A total of 11 control and 6 narcolepsy brains were analyzed by microarray (<xref ref-type="table" rid="pone-0004254-t001">Table 1</xref>). To validate our methods, we first compared transcript abundance across brain regions in control samples and identified brain region specific transcripts (<xref ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>). Of the 7 identified genes with putative preferential expression in the posterior hypothalamus, three are known to be restricted to this region: prepromelanin concentrating hormone, preprohypocretin, and histidine decarboxylase. Likewise, arginine vasopressin and oxytocin are expressed in the anterior hypothalamus. In the locus coeruleus (LC) where 14 genes were found to be region specific, seven, including dopamine-&#x003b2;-hydroxylase and tyrosine hydroxylase, are known to be expressed specifically in the LC. These results offered a strong validation of sample selection, dissection, array experiment procedure and the statistical analysis methods used in this study. (<xref ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>)</p><table-wrap id="pone-0004254-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.t001</object-id><label>Table 1</label><caption><title>Demographic and RNA quality data of human brain tissue used for analysis.</title></caption><graphic id="pone-0004254-t001-1" xlink:href="pone.0004254.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004254-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">ID</td><td align="left" rowspan="1" colspan="1">cause of death</td><td align="left" rowspan="1" colspan="1">age</td><td align="left" rowspan="1" colspan="1">sex</td><td align="left" rowspan="1" colspan="1">PMI (h)</td><td align="left" rowspan="1" colspan="1">brain pH</td><td align="left" rowspan="1" colspan="1">28S/18S</td><td align="left" rowspan="1" colspan="1">DQB1</td><td align="left" rowspan="1" colspan="1">DQB1</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">C1</td><td align="left" rowspan="1" colspan="1">not available</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">6.76</td><td align="left" rowspan="1" colspan="1">0.62</td><td align="left" rowspan="1" colspan="1">0302</td><td align="left" rowspan="1" colspan="1">0502</td></tr><tr><td align="left" rowspan="1" colspan="1">C2</td><td align="left" rowspan="1" colspan="1">colon cancer</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">48.0</td><td align="left" rowspan="1" colspan="1">6.93</td><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">0301</td><td align="left" rowspan="1" colspan="1">0301</td></tr><tr><td align="left" rowspan="1" colspan="1">C5</td><td align="left" rowspan="1" colspan="1">prostate cancer</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">48.0</td><td align="left" rowspan="1" colspan="1">6.72</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0201</td><td align="left" rowspan="1" colspan="1">0604</td></tr><tr><td align="left" rowspan="1" colspan="1">C7</td><td align="left" rowspan="1" colspan="1">cerebellum cancer meningitis</td><td align="left" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">6.62</td><td align="left" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">0301</td><td align="left" rowspan="1" colspan="1">0501</td></tr><tr><td align="left" rowspan="1" colspan="1">C8</td><td align="left" rowspan="1" colspan="1">kindey cancer; metabolic encephalopathy</td><td align="left" rowspan="1" colspan="1">75</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">8.0</td><td align="left" rowspan="1" colspan="1">6.74</td><td align="left" rowspan="1" colspan="1">0.77</td><td align="left" rowspan="1" colspan="1">0201</td><td align="left" rowspan="1" colspan="1">0303</td></tr><tr><td align="left" rowspan="1" colspan="1">C10</td><td align="left" rowspan="1" colspan="1">breast cancer</td><td align="left" rowspan="1" colspan="1">48</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">12.5</td><td align="left" rowspan="1" colspan="1">6.64</td><td align="left" rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">0503</td><td align="left" rowspan="1" colspan="1">0603</td></tr><tr><td align="left" rowspan="1" colspan="1">C12</td><td align="left" rowspan="1" colspan="1">chronic obstructive pulmonary disease</td><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">5.0</td><td align="left" rowspan="1" colspan="1">6.78</td><td align="left" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0201</td></tr><tr><td align="left" rowspan="1" colspan="1">C13</td><td align="left" rowspan="1" colspan="1">dementia</td><td align="left" rowspan="1" colspan="1">92</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">7.0</td><td align="left" rowspan="1" colspan="1">6.91</td><td align="left" rowspan="1" colspan="1">0.65</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0602</td></tr><tr><td align="left" rowspan="1" colspan="1">C14</td><td align="left" rowspan="1" colspan="1">heart failure</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">6.0</td><td align="left" rowspan="1" colspan="1">6.6</td><td align="left" rowspan="1" colspan="1">0.53</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0602</td></tr><tr><td align="left" rowspan="1" colspan="1">C15</td><td align="left" rowspan="1" colspan="1">heart failure</td><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">8.2</td><td align="left" rowspan="1" colspan="1">6.66</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0301</td></tr><tr><td align="left" rowspan="1" colspan="1">C16</td><td align="left" rowspan="1" colspan="1">not available</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">6.63</td><td align="left" rowspan="1" colspan="1">0.54</td><td align="left" rowspan="1" colspan="1">0201</td><td align="left" rowspan="1" colspan="1">0301</td></tr><tr><td align="left" rowspan="1" colspan="1">N4</td><td align="left" rowspan="1" colspan="1">not available</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">6.63</td><td align="left" rowspan="1" colspan="1">0.95</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0201</td></tr><tr><td align="left" rowspan="1" colspan="1">N5</td><td align="left" rowspan="1" colspan="1">lung cancer</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">6.76</td><td align="left" rowspan="1" colspan="1">1.48</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0603</td></tr><tr><td align="left" rowspan="1" colspan="1">N6</td><td align="left" rowspan="1" colspan="1">dementia</td><td align="left" rowspan="1" colspan="1">58</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">42.0</td><td align="left" rowspan="1" colspan="1">6.55</td><td align="left" rowspan="1" colspan="1">0.87</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0602</td></tr><tr><td align="left" rowspan="1" colspan="1">N7</td><td align="left" rowspan="1" colspan="1">dementia</td><td align="left" rowspan="1" colspan="1">89</td><td align="left" rowspan="1" colspan="1">F</td><td align="left" rowspan="1" colspan="1">20.0</td><td align="left" rowspan="1" colspan="1">6.53</td><td align="left" rowspan="1" colspan="1">1.12</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0201</td></tr><tr><td align="left" rowspan="1" colspan="1">N8</td><td align="left" rowspan="1" colspan="1">not available</td><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">1.21</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0303</td></tr><tr><td align="left" rowspan="1" colspan="1">N101</td><td align="left" rowspan="1" colspan="1">epidural hemmorage</td><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1">M</td><td align="left" rowspan="1" colspan="1">10.5</td><td align="left" rowspan="1" colspan="1">6.75</td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0602</td><td align="left" rowspan="1" colspan="1">0502</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>Age and gender distribution, postmortem interval (PMI) and brain pH are not significantly different between narcoleptic subjects (N4&#x02013;N101) and controls (C1&#x02013;C16).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Identification of transcripts dysregulated in human narcolepsy</title><p>In the comparison of narcolepsy <italic>vs</italic> control posterior hypothalami, a total of 35 downregulated and 11 upregulated genes were identified by analysis of microarray expression data. Of these, only nine genes were confirmed by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (QRT-PCR), all of which were downregulated in narcolepsy. Hypocretin was the most significantly decreased gene by Significance Analysis of Microarray (SAM) <xref ref-type="bibr" rid="pone.0004254-Tusher1">&#x0005b;15&#x0005d;</xref> ranking, and was second in terms of mean fold change. QRT-PCR confirmation indicated a dramatic 57.4 fold decrease in preprohypocretin transcript abundance, identifying the known central feature of narcolepsy. The eight other confirmed candidates, leiomodin 1 (LMOD1), cold shock domain protein A (CSDA), G protein-coupled receptor 4 (GPR4), endothelin 1 (EDN1), neuropeptide Y (NPY), growth arrest and DNA-damage-inducible, beta (GADD45B), interleukin 1 recptor-like 1 (IL1RL1) and insulin-like growth factor binding protein 3 (IGFBP3) were downregulated 1.6 to 6.1 fold (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>).</p><table-wrap id="pone-0004254-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.t002</object-id><label>Table 2</label><caption><title>Human narcolepsy susceptibility candidate genes analyzed by microarray, quantitative RT-PCR and distribution shown by <italic>in situ</italic> hybridization in mice.</title></caption><graphic id="pone-0004254-t002-2" xlink:href="pone.0004254.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004254-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td colspan="6" align="left" rowspan="1">Microarray data</td><td colspan="4" align="left" rowspan="1">Quantitative RT-PCR data</td><td colspan="2" align="left" rowspan="1"><italic>In situ</italic> hybridization data</td></tr><tr><td align="left" rowspan="1" colspan="1">Affymetrix Probe ID</td><td align="left" rowspan="1" colspan="1">Gene Name (Gene Symbol)</td><td align="left" rowspan="1" colspan="1">Chip</td><td align="left" rowspan="1" colspan="1">SAM #</td><td align="left" rowspan="1" colspan="1">1/fold change</td><td align="left" rowspan="1" colspan="1">P (u-test)</td><td align="left" rowspan="1" colspan="1">Taqman probe ID</td><td align="left" rowspan="1" colspan="1">judgement</td><td align="left" rowspan="1" colspan="1">1/fc</td><td align="left" rowspan="1" colspan="1">P (u-test)</td><td align="left" rowspan="1" colspan="1">clone ID</td><td align="left" rowspan="1" colspan="1">Localization in hyoocretin area</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">206211_at</td><td align="left" rowspan="1" colspan="1">selectin E (SELE)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">9.1</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">Hs00174057_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.3</td><td align="left" rowspan="1" colspan="1">0.167</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n.t.</td></tr><tr><td align="left" rowspan="1" colspan="1">207642_at</td><td align="left" rowspan="1" colspan="1">hypocretin (HCRT)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">8.7</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">Hs00533664_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">57.4</td><td align="left" rowspan="1" colspan="1">0.002</td><td align="left" rowspan="1" colspan="1">6974695</td><td align="left" rowspan="1" colspan="1">expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">206346_at</td><td align="left" rowspan="1" colspan="1">prolactin receptor (PRLR)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">Hs00168739_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">5055400</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">203766_s_at</td><td align="left" rowspan="1" colspan="1">leiomodin1 (smooth muscle) (LMOD1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="left" rowspan="1" colspan="1">0.013</td><td align="left" rowspan="1" colspan="1">Hs00201704_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">3810437</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">238018_at</td><td align="left" rowspan="1" colspan="1">hypothetical protein LOC285016</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4.4</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">Hs01050040_g1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.3</td><td align="left" rowspan="1" colspan="1">0.366</td><td align="left" rowspan="1" colspan="1">5060814</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">235852_at</td><td align="left" rowspan="1" colspan="1">stonin 2 (STN2)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">Hs00263833_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">6475895</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">201161_s_at</td><td align="left" rowspan="1" colspan="1">cold shock domain protein A (CSDA)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">0.081</td><td align="left" rowspan="1" colspan="1">Hs01124963_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">0.014</td><td align="left" rowspan="1" colspan="1">6581631</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">231044_at</td><td align="left" rowspan="1" colspan="1">RP5-1065J22.5 (LOC127003)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n.t.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1746040</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">241682_at</td><td align="left" rowspan="1" colspan="1">kelch-like 23 (KLHL23)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">77</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0.268</td><td align="left" rowspan="1" colspan="1">Hs00826289_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">0.519</td><td align="left" rowspan="1" colspan="1">6818752</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">222507_s_at</td><td align="left" rowspan="1" colspan="1">TMEM9 domain family, member B (TMEM9B)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="left" rowspan="1" colspan="1">Hs00221018_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0.465</td><td align="left" rowspan="1" colspan="1">5347159</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">223333_s_at</td><td align="left" rowspan="1" colspan="1">angiopoietin-like 4 (ANGPTL4)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">Hs00211522_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.201</td><td align="left" rowspan="1" colspan="1">5148869</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">226814_at</td><td align="left" rowspan="1" colspan="1">ADAM metallopeptidase with thrombospondin type 1 motif, 9 (ADAMTS9)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">Hs00172025_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.302</td><td align="left" rowspan="1" colspan="1">3999494</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">206236_at</td><td align="left" rowspan="1" colspan="1">G protein-coupled receptor 4 (GPR4)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3.4</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">Hs00270999_s1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.053</td><td align="left" rowspan="1" colspan="1">4038700</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">227697_at</td><td align="left" rowspan="1" colspan="1">suppressor of cytokine signaling 3 (SOCS3)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">Hs00269575_s1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">0.121</td><td align="left" rowspan="1" colspan="1">6830087</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">217414_x_at</td><td align="left" rowspan="1" colspan="1">hemoglobin, alpha 2 (HBA2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">Hs00361191_gl</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.068</td><td align="left" rowspan="1" colspan="1">5053650</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">206512_at</td><td align="left" rowspan="1" colspan="1">U2 small nuclear RNA auxillary factor 1-like 1 (U2AF1L1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">3.2</td><td align="left" rowspan="1" colspan="1">0.282</td><td align="left" rowspan="1" colspan="1">Hs00428253_g1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.9</td><td align="left" rowspan="1" colspan="1">0.465</td><td align="left" rowspan="1" colspan="1">6822265</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">230828_at</td><td align="left" rowspan="1" colspan="1">GRAM domain containing 2 (GRAMD2/LOC196996)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">Hs01584657_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.8</td><td align="left" rowspan="1" colspan="1">0.197</td><td align="left" rowspan="1" colspan="1">890859</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">241534_at</td><td align="left" rowspan="1" colspan="1">ATPase, class I, type 8B, member 1 (ATP8B1)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">91</td><td align="left" rowspan="1" colspan="1">3.1</td><td align="left" rowspan="1" colspan="1">0.149</td><td align="left" rowspan="1" colspan="1">Hs00194444_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">0.121</td><td align="left" rowspan="1" colspan="1">6308651</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">228766_at</td><td align="left" rowspan="1" colspan="1">CD36 molecule (thrombospondin receptor) (CD36)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">47</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.106</td><td align="left" rowspan="1" colspan="1">Hs00169627_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.1</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">3481681</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">211699_x_at</td><td align="left" rowspan="1" colspan="1">chromosome 11 open reading frame 70 (C11orf70/MGC13040)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.048</td><td align="left" rowspan="1" colspan="1">Hs00262911_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.6</td><td align="left" rowspan="1" colspan="1">0.366</td><td align="left" rowspan="1" colspan="1">6334520</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">222802_at</td><td align="left" rowspan="1" colspan="1">endothelin 1 (EDN1)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">2.8</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">Hs00174961_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">3.0</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">6824438</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">206001_at</td><td align="left" rowspan="1" colspan="1">neuropeptide Y (NPY)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">Hs00173470_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">3.5</td><td align="left" rowspan="1" colspan="1">0.039</td><td align="left" rowspan="1" colspan="1">5683102</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">207896_s_at</td><td align="left" rowspan="1" colspan="1">deleted in lung and eshophageal cancer 1 (DLEC1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">0.181</td><td align="left" rowspan="1" colspan="1">Hs00201098_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">0.366</td><td align="left" rowspan="1" colspan="1">872087</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">231830_x_at</td><td align="left" rowspan="1" colspan="1">RAB11 family interacting protein 1 (class I) (RAB11FIP1)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">2.7</td><td align="left" rowspan="1" colspan="1">0.048</td><td align="left" rowspan="1" colspan="1">Hs00368787_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.0</td><td align="left" rowspan="1" colspan="1">0.914</td><td align="left" rowspan="1" colspan="1">4945175</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">209304_x_at</td><td align="left" rowspan="1" colspan="1">growht arrestand DNA-damage-inducible, beta (GADD45B)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.005</td><td align="left" rowspan="1" colspan="1">Hs00169587_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">2.2</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">5032648</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">236894_at</td><td align="left" rowspan="1" colspan="1">LINE-1 type transposase domain containing 1 (L1TD1/ECAT11)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.034</td><td align="left" rowspan="1" colspan="1">Hs00219458_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">undet</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">962927</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">236034_at</td><td align="left" rowspan="1" colspan="1">microcephaly, primary autosomal recessive 1 (MCPH1)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.030</td><td align="left" rowspan="1" colspan="1">Hs00226253_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.8</td><td align="left" rowspan="1" colspan="1">0.361</td><td align="left" rowspan="1" colspan="1">6416651</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">203548_s_at</td><td align="left" rowspan="1" colspan="1">lipoprotein lipase (LPL)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.081</td><td align="left" rowspan="1" colspan="1">Hs00173425_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">0.584</td><td align="left" rowspan="1" colspan="1">6315514</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">211775_x_at</td><td align="left" rowspan="1" colspan="1">hypothetical MGC13053</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">0.043</td><td align="left" rowspan="1" colspan="1">Hs00707696_s1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">0.273</td><td align="left" rowspan="1" colspan="1">2937689</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">206091_at</td><td align="left" rowspan="1" colspan="1">matrilin 3 (MATN3)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.020</td><td align="left" rowspan="1" colspan="1">Hs00159081_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.7</td><td align="left" rowspan="1" colspan="1">0.302</td><td align="left" rowspan="1" colspan="1">6306229</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">239151_at</td><td align="left" rowspan="1" colspan="1">hypothetical protein LOC255326</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.015</td><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n.t.</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">n/a</td><td align="left" rowspan="1" colspan="1">n.t.</td></tr><tr><td align="left" rowspan="1" colspan="1">212143_s_at</td><td align="left" rowspan="1" colspan="1">insulin-like growth factor binding protein 3 (IGFBP3)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.001</td><td align="left" rowspan="1" colspan="1">Hs00181211_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">2.0</td><td align="left" rowspan="1" colspan="1">0.010</td><td align="left" rowspan="1" colspan="1">6437611</td><td align="left" rowspan="1" colspan="1">expressed</td></tr><tr><td align="left" rowspan="1" colspan="1">207526_s_at</td><td align="left" rowspan="1" colspan="1">interleukin 1 receptor-like 1 (IL1RL1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.081</td><td align="left" rowspan="1" colspan="1">Hs00545033_m1</td><td align="left" rowspan="1" colspan="1">validated</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="left" rowspan="1" colspan="1">0.028</td><td align="left" rowspan="1" colspan="1">MGC 30073421</td><td align="left" rowspan="1" colspan="1">n.e.</td></tr><tr><td align="left" rowspan="1" colspan="1">218775_s_at</td><td align="left" rowspan="1" colspan="1">WW, C2 and coiled-coil domain containing 2 (WWC2/BOMB)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.181</td><td align="left" rowspan="1" colspan="1">Hs00227904_m1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.2</td><td align="left" rowspan="1" colspan="1">0.273</td><td align="left" rowspan="1" colspan="1">5142576</td><td align="left" rowspan="1" colspan="1">n.c.</td></tr><tr><td align="left" rowspan="1" colspan="1">231728_at</td><td align="left" rowspan="1" colspan="1">calcyphosine (CAPS)</td><td align="left" rowspan="1" colspan="1">B</td><td align="left" rowspan="1" colspan="1">65</td><td align="left" rowspan="1" colspan="1">2.5</td><td align="left" rowspan="1" colspan="1">0.268</td><td align="left" rowspan="1" colspan="1">Hs00362033_g1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">1.000</td><td align="left" rowspan="1" colspan="1">not expr. in rodents</td><td align="left" rowspan="1" colspan="1">n.t.</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>n.t.; not tested, n.e.; no expression, n.c.; no coexpression in perifornical hypocretin area.</p></fn><fn id="nt103"><p>probe set ID is from aAffymetrix, QRT-PCR probe ID is from Applied Biosystems, and All clones for in situ hybridization are IMAGE clones except where noted.</p></fn><fn id="nt104"><p>Gene expression was compared between 6 narcolepsy and 8 control postmortem posterior hyptothalami (A and B Genechip). Narcolepsy candidate genes selected by statistical analysis of microarray data are listed at left, quantitative RT-PCR results are in the center, and results of <italic>in situ</italic> hybridization in mouse hypothalamus are at the right. As only downregulated genes were confirmed by RT-PCR studies, upregulated candidates are not shown. Genes labeled with &#x0201c;validated&#x0201d; were confirmed as narcolepsy related genes. Note that <italic>IGFBP3</italic> is the only gene validated by QRT-PCR and showing a hypocretin-like distribution pattern. Some candidates showed uniform signal over the whole brain section, potentially indicating ubiquitous expression, but we regarded the staining as background and classified the gene as not expressed if no anatomical variation in staining level was observed.</p></fn></table-wrap-foot></table-wrap><p>Previously known HCRT co-expressed genes were not reported in our analysis either because they were not listed within the top 100 SAM ranked candidates (<italic>NPTX2</italic>, <italic>GAL</italic> (galanin), and <italic>CART</italic> (cocaine and amphetamine regulated transcript), or expression was classified as &#x0201c;absent&#x0201d; (<italic>PDYN</italic>) using the microarray suite software (MAS) 5.0 algorithm. The array signals for these genes were decreased (<italic>PDYN</italic>: 2.4 fold, p&#x0200a;&#x0003d;&#x0200a;0.005; <italic>NPTX2</italic>: 1.3 fold, p&#x0200a;&#x0003d;&#x0200a;0.5; <italic>GAL</italic>: 2.3 fold, p&#x0200a;&#x0003d;&#x0200a;0.06; <italic>CART</italic>: 1.2 fold, p&#x0200a;&#x0003d;&#x0200a;0.36) as were the QRT-PCR comparisons (<italic>PDYN</italic>: 1.8 fold, p&#x0200a;&#x0003d;&#x0200a;0.03; <italic>NPTX2</italic>: 1.6 fold, p&#x0200a;&#x0003d;&#x0200a;0.07; <italic>GAL</italic>: 1.9 fold, p&#x0200a;&#x0003d;&#x0200a;0.09; <italic>CART</italic>: 1.3 fold, p&#x0200a;&#x0003d;&#x0200a;0.24). These results further validated our method.</p></sec><sec id="s2c"><title>IGFBP3 is co-localized in hypocretin producing cells in mouse brains</title><p><italic>In situ</italic> hybridization (ISH) of all human putative downregulated genes was performed in mice (C57/BL/6J) (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>). Of the 8 candidates confirmed by QRT-PCR as downregulated in narcolepsy brains, only one gene, Insulin-like Growth Factor Binding Protein-3 (<italic>Igfbp 3</italic>), was clearly enriched in the perifornical region where HCRT neurons are located (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>). Among the other genes, many did not appear to be expressed at all in the studied brain regions or the expression was restricted to regions other than the perifornical area (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>).</p><fig id="pone-0004254-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.g001</object-id><label>Figure 1</label><caption><title>IGFBP3 signals in wild type, ataxin-3 hemizygous, and hypocretin KO mice.</title><p>The upper panel shows IGFBP3 ISH staining in wild type (A: WT), ataxin-3 hemizygous (B:HZ) and HCRT knockout (C: KO) mice. HCRT staining in neurons (arrowheads) is markedly reduced or absent in the ataxin-3 mouse. The lower panel shows IGFPB3 ISH signal (D: purple; digoxigenin staining with BCIP/NBT), HCRT fluorescence (E: red; Alexa Fluor) immunostaining, and a composite picture (F), indicating that many hypocretin neurons (asterisks) are positive for IGFBP3 in a WT mouse. Scale bar 20 &#x000b5;m.</p></caption><graphic xlink:href="pone.0004254.g001"/></fig><p>To determine if IGFPB3 is selectively expressed by HCRT neurons in the perifornical area, we used <italic>Hcrt</italic>-ataxin-3 hemizygous (HZ) transgenic <xref ref-type="bibr" rid="pone.0004254-Hara1">&#x0005b;6&#x0005d;</xref>, and <italic>Hcrt</italic> knock-out (KO) mice <xref ref-type="bibr" rid="pone.0004254-Chemelli1">&#x0005b;4&#x0005d;</xref>. When we performed ISH with <sup>35</sup>S-probes and exposed X-ray film to these slides, signal in the perifornical area was visible after 4 day exposure in the littermate wild type (WT) mice, whereas this region remained invisible after 40 days of exposure in ataxin-3 mice (<xref ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>). Loss of HCRT peptide in ataxin-3 mice could potentially induce secondary changes in gene expression in neighboring cells. Therefore we studied <italic>Hcrt</italic> KO mice and found that <italic>Igfbp3</italic> expression was similar to that of WT mice (<xref ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>) indicating that loss of HCRT peptide itself did not induce changes in <italic>Igfbp3</italic> expression.</p><p>To investigate coexpression of HCRT and <italic>Igfbp3</italic>, we performed <italic>Igfbp3</italic> ISH followed by HCRT immunostaining. Colocalization of both signals was seen in a majority (&#x0223c;80&#x00025;) of hypocretin neurons (<xref ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>). Using this technique, we also surveyed <italic>Igfbp3</italic> expression throughout the mouse brain. Significant <italic>Igfbp3</italic> expression was restricted to a few brain areas including posterior hypothalamus, cerebellar Purkinje neurons, and a group of cells in the pons localized in or close to the pedunculopontine nucleus. Weaker signal was also seen in the ventromedial hypothalamus, granular and pyramidal layers of the hippocampus, and endopiriform nucleus. Expression in all regions other than posterior hypothalamic area was unaffected in the <italic>Hcrt</italic>-ataxin-3 hemizygous (HZ) mice.</p></sec><sec id="s2d"><title>IGFBP3 is localized in human hypocretin producing cells</title><p>IGFBP3 immunoreactivity was surveyed using various antibodies (after screening selectivity by western blot) through an entire human hypothalamic block. Blood vessels gave strong signal with IGFBP3 antibody, possibly due to residual blood which has very high IGFBP3 content. Other cells, mostly of non-neuronal origin and negative for the NeuN neuronal marker were also stained. Cellular IGFBP3 staining of NeuN positive large neurons was only noted in the perifornical area. IGFBP3 and HCRT double immunostaining detected colocalization in 10&#x02013;20&#x00025; of HCRT neurons in the perifornical area (<xref ref-type="fig" rid="pone-0004254-g002">Fig. 2</xref>). All neurons showing colocalization of IGFBP3 and HCRT appeared to have a reduced hypocretin signal. Double-stained fibers were also observed in multiple other hypothalamic areas. This colocalization was also seen in some of the few remaining HCRT neurons in brains from narcolepsy patients.</p><fig id="pone-0004254-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.g002</object-id><label>Figure 2</label><caption><title>Colocalization of IGFBP3 in HCRT cells in control and narcolepsy human brain.</title><p>Upper panel: Distribution of hypocretin cells and fibers in the perifornical area of human hypothalamus. (A) In control brains, HCRT cells and fibers were densely stained by an anti-HCRT monoclonal antibody (red fluorescence: VectorRed), while in narcolepsy brains, staining was markedly reduced (B) Lower panel: HCRT immunoreactivity (C: red fluorescence) and IGFBP3 immunoreactivity (D: green fluorescene; Q-dot525) and a composite picture (E) arrows indicate HCRT cells colocalized with IGFBP3). Note non-neuronal autofluorescent elements. Scale bar: 500 &#x000b5;m in A and B, 100 &#x000b5;m in C, D and E.</p></caption><graphic xlink:href="pone.0004254.g002"/></fig></sec><sec id="s2e"><title>Identification of transcripts downregulated in the hypocretin-ataxin-3 hemizygous transgenic mouse model</title><p>Gene expression in perifornical posterior hypothalamus was compared in <italic>Hcrt</italic>-ataxin-3 transgenic mice lacking most hypocretin neurons versus wild type animals (two pools of 30 mice). Transcripts with the highest fold changes are reported in <xref ref-type="table" rid="pone-0004254-t003">Table 3</xref>. Genes with known colocalization, such as NPTX2 and dynorphin, were downregulated, validating the model. Other transcripts were also found (<xref ref-type="table" rid="pone-0004254-t003">Table 3</xref>), only one of which, IGFBP3, was downregulated in human narcolepsy hypothalami. For this reason, functional studies involving IGFBP3 and hypocretin were next carried out.</p><table-wrap id="pone-0004254-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.t003</object-id><label>Table 3</label><caption><title>Mouse transcripts most differentially dysregulated in the perifornical area of ataxin-3 transgenic animals versus control mice.</title></caption><graphic id="pone-0004254-t003-3" xlink:href="pone.0004254.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004254-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Affymetrix Probe ID</td><td align="left" rowspan="1" colspan="1">Gene name (Gene symbol)</td><td align="left" rowspan="1" colspan="1">Chip</td><td align="left" rowspan="1" colspan="1">1/Fold change</td></tr></thead><tbody><tr><td colspan="4" align="left" rowspan="1"><bold>Decreased in Hz</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">448821_at</td><td align="left" rowspan="1" colspan="1">Tyrosinase (Tyr)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">34.3</td></tr><tr><td align="left" rowspan="1" colspan="1">452022_at</td><td align="left" rowspan="1" colspan="1">BAALC isoform 1-6-8 (Baalc)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">27.9</td></tr><tr><td align="left" rowspan="1" colspan="1">422411_s_at</td><td align="left" rowspan="1" colspan="1">Eosinophil-associated ribonuclease 3 (Ear3)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">16.0</td></tr><tr><td align="left" rowspan="1" colspan="1">418353_at</td><td align="left" rowspan="1" colspan="1">CD5 antigen (Cd5)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" rowspan="1" colspan="1">416128_at</td><td align="left" rowspan="1" colspan="1">Tubulin, alpha 6 (Tuba6)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">9.2</td></tr><tr><td align="left" rowspan="1" colspan="1">426003_at</td><td align="left" rowspan="1" colspan="1">Neurotrophin-3 receptor non-catalytic isoform 1 (trkC)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">8.6</td></tr><tr><td align="left" rowspan="1" colspan="1">451014_at</td><td align="left" rowspan="1" colspan="1">Receptor tyrosine kinase-like orphan receptor 1 (Ror1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">8.0</td></tr><tr><td align="left" rowspan="1" colspan="1">450772_at</td><td align="left" rowspan="1" colspan="1">Wingless-related MMTV integration site 11 (Wnt11)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">7.5</td></tr><tr><td align="left" rowspan="1" colspan="1">416266_at</td><td align="left" rowspan="1" colspan="1">Prodynorphin (Pdyn)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">5.7</td></tr><tr><td align="left" rowspan="1" colspan="1">418035_a_at</td><td align="left" rowspan="1" colspan="1">DNA primase, p58 subunit (Prim2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">420471_at</td><td align="left" rowspan="1" colspan="1">Hypocretin (Hcrt)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">439199_at</td><td align="left" rowspan="1" colspan="1">Protein phosphatase 2a, catalytic subunit, alpha isoform (Ppp2ca)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">437618_x_at</td><td align="left" rowspan="1" colspan="1">G protein-coupled receptor 85 (Gpr85)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4.9</td></tr><tr><td align="left" rowspan="1" colspan="1">421767_at</td><td align="left" rowspan="1" colspan="1">Adenosine kinase (Adk)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4.6</td></tr><tr><td align="left" rowspan="1" colspan="1">450091_at</td><td align="left" rowspan="1" colspan="1">Immunoglobulin mu binding protein 2 (Ighmbp2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" rowspan="1" colspan="1">427168_a_at</td><td align="left" rowspan="1" colspan="1">Collagen type XIV (Col14a1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">4.0</td></tr><tr><td align="left" rowspan="1" colspan="1">437502_x_at</td><td align="left" rowspan="1" colspan="1">CD24a antigen (Cd24a)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.7</td></tr><tr><td align="left" rowspan="1" colspan="1">432129_a_at</td><td align="left" rowspan="1" colspan="1">Paired related homeobox 1 (Prrx1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.7</td></tr><tr><td align="left" rowspan="1" colspan="1">450315_at</td><td align="left" rowspan="1" colspan="1">Pheromone receptor V3R8 (V3R8)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">455639_at</td><td align="left" rowspan="1" colspan="1">Rap2 interacting protein (Rap2ip)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.5</td></tr><tr><td align="left" rowspan="1" colspan="1">423062_at</td><td align="left" rowspan="1" colspan="1"><bold>Insulin-like growth factor binding protein 3 (Igfbp3)</bold></td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">435950_at</td><td align="left" rowspan="1" colspan="1">Periplakin (Ppl)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">421516_at</td><td align="left" rowspan="1" colspan="1">Orphan receptor RTR (Nr6a1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">419628_at</td><td align="left" rowspan="1" colspan="1">Ceh-10 homeo domain containing homolog (Ch&#x000d7;10)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" rowspan="1" colspan="1">450533_a_at</td><td align="left" rowspan="1" colspan="1">Zinc finger protein regulator of apoptosis and cell cycle arrest (Zac1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">3.0</td></tr><tr><td align="left" rowspan="1" colspan="1">427835_at</td><td align="left" rowspan="1" colspan="1">Transcription factor Oct-1 isoform 7 (Pou2f1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">423026_at</td><td align="left" rowspan="1" colspan="1">Rad51 homolog c (Rad51c)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">425175_at</td><td align="left" rowspan="1" colspan="1">Gliacolin (C1ql3)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.8</td></tr><tr><td align="left" rowspan="1" colspan="1">425886_at</td><td align="left" rowspan="1" colspan="1">ETS-domain transcription factor (Fev)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">418494_at</td><td align="left" rowspan="1" colspan="1">Early B-cell factor 2 (Ebf2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">426180_a_at</td><td align="left" rowspan="1" colspan="1">MSG2alpha salivary protein (Vcs2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">452380_at</td><td align="left" rowspan="1" colspan="1">Ephrin receptor A7 (Epha7)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" rowspan="1" colspan="1">419221_a_at</td><td align="left" rowspan="1" colspan="1">Regulator of G-protein signaling 14 (Rgs14)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">449960_at</td><td align="left" rowspan="1" colspan="1">Neuronal pentraxin 2 (Nptx2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">421109_at</td><td align="left" rowspan="1" colspan="1">Camello-like 2 (Cml2)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">460354_a_at</td><td align="left" rowspan="1" colspan="1">Mitochondrial ribosomal protein L13 (L13mt)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">427832_at</td><td align="left" rowspan="1" colspan="1">Testicular alpha tubulin (Tuba-rs1)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">2.5</td></tr><tr><td colspan="4" align="left" rowspan="1"><bold>Increased in Hz</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">418162_at</td><td align="left" rowspan="1" colspan="1">Toll-like receptor 4 (Tlr4)</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">19.7</td></tr></tbody></table><table-wrap-foot><fn id="nt105"><p>The perifornical area of 30 wild type and 30 ataxin-3 transgenic mice lacking hypocretin cells were punched (see <xref ref-type="supplementary-material" rid="pone.0004254.s003">Fig. S1</xref>) and samples pooled to perform microarray experiments. <italic>Hcrt</italic>-ataxin-3 transgenic mouse dysregulated genes are listed by order of transcript abundance (fold change). Most transcripts were decreased in <italic>Hcrt</italic>-ataxin-3 mice, some of which are known to be colocalized with hypocretin (NPTX2, dynorphin). Note that IGFBP3, which was identified by expression profiling using human hypothalami, was also decreased in this experiment.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2f"><title>Evaluation of IGFBP3 levels, genotype, and IGFBP3 antibodies in blood and CSF of narcoleptic patients</title><p>We investigated whether human narcolepsy is associated with dysregulated IGFBP3 levels in the blood and CSF. Mean levels of IGFBP3 in age and sex matched narcolepsy patients (all with low CSF hypocretin-1) versus controls were 59.4&#x000b1;3.4 ng/ml (n&#x0200a;&#x0003d;&#x0200a;11) and 58.0&#x000b1;4.5 (n&#x0200a;&#x0003d;&#x0200a;11) ng/ml in serum and 31.2&#x000b1;2.1 ng/ml (n&#x0200a;&#x0003d;&#x0200a;27) and 29.0&#x000b1;1.9 ng/ml (n&#x0200a;&#x0003d;&#x0200a;35) in CSF respectively. As previously reported <xref ref-type="bibr" rid="pone.0004254-Bunn1">&#x0005b;16&#x0005d;</xref>, levels of IGFBP3 correlated with age but not sex in adults. After controlling for these factors, there was no significant difference in age of onset.</p><p>A single base polymorphism in the <italic>IGFBP3</italic> promoter region (rs 2854744) strongly correlates with plasma IGFBP3 <xref ref-type="bibr" rid="pone.0004254-Jernstrom1">&#x0005b;17&#x0005d;</xref> levels. We tested whether this IGFBP3 polymorphism is associated with human narcolepsy-cataplexy by testing 130 trios using the transmission disequilibrium test (TDT). No difference in transmission was observed (53.5&#x00025; versus 46.5&#x00025; for the A allele; Chi sq&#x0200a;&#x0003d;&#x0200a;0.77, p&#x0200a;&#x0003d;&#x0200a;0.38).</p><p>We also explored the possibility that autoantibodies directed against IGFBP3 could be identified. We expressed human IGFBP3 in COS cells, and extracted proteins were western blotted. The resulting membrane was incubated with sera from 22 human narcoleptic and 20 control subjects and revealed with anti human IgG. None of the patients (some with disease onset less than a year prior to blood sampling) or controls had specific reactivity to expressed IGFBP3.</p></sec><sec id="s2g"><title>IGFBP3 inhibits hypocretin production <italic>in vivo</italic></title><p>To investigate whether IGFBP3 regulates hypocretin cell physiology and sleep <italic>in vivo</italic>, we studied IGFBP3 knockout mice (<italic>mIgfbp3 KO</italic>: C57BL/6J strain) <xref ref-type="bibr" rid="pone.0004254-Ning1">&#x0005b;18&#x0005d;</xref> and two human IGFBP3 transgenic lines ( CD-1 strain) <xref ref-type="bibr" rid="pone.0004254-Modric1">&#x0005b;19&#x0005d;</xref>: a transgenic mouse strain overexpressing human IGFBP3 (<italic>hIGFBP3</italic> transgenic), and a transgenic strain overexpressing a mutated form of hIGFBP3 that does not bind IGF (<italic>hmutIGFBP3</italic> transgenic) <xref ref-type="bibr" rid="pone.0004254-Silha1">&#x0005b;20&#x0005d;</xref>. These two lines allowed us to distinguish IGF dependent and independent effects of IGFBP3. Quantitative PCR analysis of human IGFBP3 transcripts in the hypothalamus of these models indicated that <italic>IGFBP3</italic> is overexpressed approximately twice in <italic>hIGFBP3</italic> transgenic animals and 10 times in <italic>hmutIGFBP3</italic> transgenic animals, but is absent in IGFBP3 knockout animals (data not shown), validating these models. Immunocytochemistry did not reveal hypocretin cell defects nor decrease in cell number in <italic>Igfbp3</italic> knockout or transgenic animals (data not shown). We next measured hypocretin-1 peptide content and hypothalamic preprohypocretin expression (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3A&#x02013;C</xref>) and found that preprohypocretin mRNA expression was significantly decreased in <italic>hIGFBP3</italic> transgenic animals compared to controls, but unaltered in the other models (including <italic>hmutIGFBP3</italic> transgenic and <italic>Igfbp3</italic> KO mice)(<xref ref-type="fig" rid="pone-0004254-g003">Fig 3A, C</xref>). Hypocretin-1 peptide contents were significantly decreased primarily in <italic>hIGFBP3</italic> transgenic and less so in <italic>humtIGFBP3</italic> transgenic mice compared to controls, indicating both IGF dependent and less prominently independent properties of IGFBP3 affect hypocretin production (<xref ref-type="fig" rid="pone-0004254-g003">Fig 3B</xref>). Hypocretin cell counts were nonetheless normal in the <italic>hIGFBP3</italic> transgenic model (3269&#x000b1;99 in HZ versus3230&#x000b1;140 in WT, n&#x0200a;&#x0003d;&#x0200a;4 each, age 8 weeks, mean&#x000b1;SEM). As a control, Melanin Concentrating Hormone (MCH) expression was also studied and found to be unaffected by <italic>hIGFBP3</italic> overexpression or <italic>Igfbp3</italic> absence (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3D</xref>).</p><fig id="pone-0004254-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.g003</object-id><label>Figure 3</label><caption><title>IGFBP3 inhibits HCRT production <italic>in vivo</italic> and <italic>in vitro</italic>.</title><p>(A, B) Hypocretin-1 peptide content is significantly decreased in both hypothalamus and brainstem of IGFBP3 overexpressing transgenic mice (h<italic>IGFBP3</italic> TG). In mutant IGFBP3 overexpressing mice (hmut<italic>IGFBP3</italic> TG), the hypocretin-1 peptide shows slight but significant decrease only in brainstem, not in hypothalamus (A, B). Hypocretin mRNA is also significantly decreased in IGFBP3 (h<italic>IGFBP3</italic> TG) mice but not in hmut<italic>IGFBP3</italic> TG mice. (C) MCH mRNA level is not affected in h<italic>IGFBP3</italic> TG or hmut<italic>IGFBP3</italic> TG TG mice.(D) IGFBP3 expression reduces preprohypocretin promotor activity in the SH-SY5Y neuroblastoma cell line, but not in non-neural cell lines (HeLa, HEK, SF126, Becker). (F). In human subjects, rs2854744, &#x02212;202 C, a promotor polymorphism allele known to be associated with reduced IGFBP3 production, is dose dependently associated with increased CSF hypocretin-1 levels. A, B: &#x0002a;: p&#x0003c;0.05; &#x0002a;&#x0002a;, p&#x0003c;0.01; &#x0002a;&#x0002a;&#x0002a;:p&#x0003c;0.001; C: &#x0002a;: p&#x0003c;0.001 versus without 3.2 kb promotor activity, #:p&#x0003c;0.001 versus promotor activity without IGFBP3; F: &#x0002a;: p&#x0003c;0.05 using ANOVA with genotype as a grouping factor. Sample numbers were indicated in parentheses.</p></caption><graphic xlink:href="pone.0004254.g003"/></fig></sec><sec id="s2h"><title>IGFBP3 overexpression increases sleep at the end of the active period</title><p>To assess whether IGFBP3 overexpression could modulate cell death, <italic>hIGFBP3</italic> transgenic mice were crossed with <italic>Hcrt</italic>-ataxin-3 transgenic mice known to develop hypocretin cell loss at 3&#x02013;6 weeks of age. Hypocretin cell counts were carried out at 8 weeks of age, and no effect of the <italic>hIGFBP3</italic> transgene was noted (595&#x000b1;36 in double HZ (hemizygous) versus 610&#x000b1;67 in <italic>Hcrt</italic>-ataxin-3/<italic>hIGFBP3</italic> HZ/WT, n&#x0200a;&#x0003d;&#x0200a;5 each). We next characterized whether overexpression of IGFBP3 and resulting effects on hypocretin transmission affect sleep and wakefulness by conducting sleep studies on <italic>hIGFBP3</italic> transgenic mice and their littermates. Although no overall significant difference in sleep amounts were observed (<xref ref-type="supplementary-material" rid="pone.0004254.s002">Table S2</xref>), we found that these animals exhibit more sleep at the end of the dark period. Sleep deprivation was also performed, and revealed a very similar recovery profile, although more sleep was again observed in transgenic animals prior to light onset (<xref ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>). Sleep studies were not performed on <italic>mIgfbp3</italic> KO mice considering the absence of significant differences in Hypocretin mRNA and peptide content in these animals (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3</xref>).</p><fig id="pone-0004254-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004254.g004</object-id><label>Figure 4</label><caption><title>Decreased wakfeluness in human IGFBP3 transgenic mice.</title><p>(A) Wakefulness is decreased in the second half of the dark/active period in human IGFBP3 transgenic mouse (h<italic>IGFBP3</italic> TG) versus wild type littermates (WT). Reduced sleep rebound is also observed at the same Zeitgeber times (ZT) after sleep deprivation. (B) Cumulative NREM plots at baseline and during recovery after 6 hours of sleep deprivation. Note increased sleep in IGFBP3 transgenic mice in the second half of the active period, ZT17-24. &#x0002a;&#x0002a;: p&#x0003c;0.01 versus WT; &#x0002a;&#x0002a;&#x0002a;: p&#x0003c;0.001 versus WT. Temperature and locomotion were also affected, see <xref ref-type="supplementary-material" rid="pone.0004254.s004">Fig. S2</xref>.</p></caption><graphic xlink:href="pone.0004254.g004"/></fig></sec><sec id="s2i"><title>IGFBP3 reduces promotor activity of hypocretin in neural cell lines</title><p>As IGFBP3 is known to have modulatory effects on transcription, for example through its binding to nur 77 <xref ref-type="bibr" rid="pone.0004254-Lee1">&#x0005b;21&#x0005d;</xref>, a possible explanation for IGFBP3 effects on sleep could be transcriptional modulation of the preprohypocretin gene. To test this hypothesis, prepro-hypocretin promotor activity was examined in several cell lines of various origins in the presence of a transfected IGFBP3 construct (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3E</xref>). We found that IGFBP3 reduced promotor activity of preprohypocretin <italic>in vitro</italic>. This effect was only observed in the neural (neuroblastoma-derived) cell line SH-SY5Y, suggesting the need for neural-specific cofactors.</p></sec><sec id="s2j"><title>An IGFBP3 polymorphism known to increase IGFBP3 serum levels is associated with reduced CSF hypocretin levels</title><p>To test whether IGFBP3 activity regulates hypocretin levels <italic>in vivo</italic>, DNA samples of 262 Caucasian subjects with normal CSF hypocretin-1 levels (&#x0003e;200 pg/ml), either drawn from healthy control subjects or from subjects with a complaint of sleepiness unexplained by hypocretin deficiency, were typed for rs2854744 (&#x02212;202A/C IGFBP3 promoter polymorphism). As previously reported, no relationship between sleepiness/disease status, age or sex and hypocretin levels were found. Interestingly however, a significant dose dependent increase in hypocretin-1 level was found with increasing doses of rs2854744 C, the allele associated with decreased IGFBP3 levels (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3F</xref>). These results suggest that this IGFBP3 polymorphism modulates hypocretin production <italic>in vivo</italic> in humans.</p></sec></sec><sec id="s3"><title>Discussion</title><p>Gene expression profiling in postmortem human brain samples using microarrays is a difficult and controversial area <xref ref-type="bibr" rid="pone.0004254-Franz1">&#x0005b;22&#x0005d;</xref>. To validate our technique, we compared transcript abundance in regions known to contain specific neurotransmitters of importance in sleep regulation. After filtering out genes with inconsistent expression, a combination of a permutation method (SAM) and descriptive quantitative ranking of fold changes was found to be the most appropriate statistical analysis. The anterior and posterior hypothalami are known to promote sleep and wake respectively. The LC area was selected as a prototypical HCRT receptor-1 bearing adrenergic cell group, while the diagonal band was selected as an HCRT receptor-2 rich area containing cholinergic neurons.</p><p>The comparison of regions showed a remarkably high expression of genes characteristic for these regions (<xref ref-type="supplementary-material" rid="pone.0004254.s001">Table S1</xref>). In the LC, for example, enriched genes included the presynaptically located &#x003b1;<sub>2A</sub>- receptors and adrenergic transporters, catecholamine synthesizing enzymes (tyrosine hydroxylase, DOPA decarboxylase and dopamine-&#x003b2;-hydroxylase) and the transcription factors <italic>PHOX2A</italic> and <italic>PHOX2B</italic> which are involved in the development of this nucleus <xref ref-type="bibr" rid="pone.0004254-VogelHopker1">&#x0005b;23&#x0005d;</xref>. Additional work is indicated to validate and study these genes, as they are potentially important in the neurobiology of these regions. It is notable that our study compared only four regions but was sufficient to effectively identify a large number of region-specific genes.</p><p>These promising results led us to compare narcolepsy and control posterior hypothalamus, the primary site of the biochemical defect in narcolepsy (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>). In this comparison we used slightly less stringent criteria with inclusion of the top 100 SAM dysregulated genes followed by QRT-PCR validation using the same brain sample sets. No genes were confirmed to be upregulated, whereas 9 of 35 candidates were confirmed as downregulated in the posterior hypothalamus of narcolepsy patients. As expected, preprohypocretin was the top candidate in this analysis, displaying a 9-fold change in expression through the array comparison and a more than 50 fold change when verified by RT-PCR (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>). This striking result suggests that if this precise neuroanatomical region had been targeted, it would have been possible to discover the central feature of narcolepsy -HCRT deficiency- without a preconceived hypothesis. A recent microarray analysis in Parkinson's disease also yielded excellent results after careful dissection of the substantia nigra <xref ref-type="bibr" rid="pone.0004254-Mandel1">&#x0005b;24&#x0005d;</xref>. Our work thus validates the use of postmortem samples for finding the cause of certain neuropsychiatric disorders, a nascent field, provided that careful selection of neuroanatomical regions is performed, as in these studies.</p><p>The posterior hypothalamic candidates were also subjected to neuroanatomical screening in mouse brain. The primary goal of this analysis was to identify genes that are coexpressed with HCRT and therefore lost in narcoleptic brains in association with death of these cells. Very few such candidates are currently known, and none is specific for HCRT neurons. Known coexpressed genes in various species include <italic>NTPX2</italic>, <italic>GAL</italic>, <italic>PDYN</italic>, <italic>ENTPD3</italic> (extonucleoside triphosphate diphosphohydrolase 3) and <italic>CART</italic>. These transcripts were not identified in our human array analysis as they either were expressed in other areas of the brain, leading to a low SAM ranking (<italic>NPTX2</italic>, <italic>GAL</italic>, <italic>CART</italic>) or because the expression was classified as absent in most samples (<italic>PDYN</italic>, <italic>ENTPD3</italic>), although the QRT-PCR analysis indicated moderately decreased expression of these genes in narcolepsy (see <xref ref-type="sec" rid="s2">results</xref>).</p><p>A combination of QRT-PCR confirmation in human hypothalamus and neuroanatomical screening in the mouse brain identified a single factor, <italic>IGFBP3</italic> that is coexpressed with <italic>HCRT</italic> in both humans and mice and present in only a few other brain areas. Confirmation of the colocalization was performed using multiple techniques in both mouse (<xref ref-type="fig" rid="pone-0004254-g001">Fig. 1</xref>) and human (<xref ref-type="fig" rid="pone-0004254-g002">Fig. 2</xref>). A combination of ISH and immunostaining showed <italic>Igfbp3</italic> expression in a majority (&#x0223c;80&#x00025;) of HCRT neurons in mice. One of the most striking findings was the observation that <italic>Igfbp3</italic> signal decreased dramatically in the perifornical hypocretin cell region of <italic>Hcrt</italic>-ataxin-3 transgenic mouse lacking most hypocretin producing cells.</p><p>Although the other 7 QRT-PCR confirmed genes in the human study were not found to be expressed in HCRT neurons, additional work will be needed to explore the importance of these genes in the pathophysiology of narcolepsy. In some cases, expression was not detected by <italic>in situ</italic> hybridization in mice but may still be present at low levels. Further, hypocretin cell loss in narcolepsy might be triggered by yet unknown changes in surrounding cells or structures. These factors would not be identified in animal models with disrupted hypocretin neurotransmission but would be downregulated in human brains. In this respect, <italic>IL1RL1</italic> may be of special interest as we found a 6.1 fold difference by QRT-PCR, and this orphan receptor has a role in immune regulation <xref ref-type="bibr" rid="pone.0004254-Coyle1">&#x0005b;25&#x0005d;</xref>. The other downregulated genes that were found, or previously known to express elsewhere (<italic>eg NPY</italic>, <italic>GPR4</italic>), may reflect physiologically important network remodeling in narcolepsy.</p><p>Double immunostaining also revealed additional IGFBP3 immunoreactive, hypocretin negative cells in human hypothalamus (both neurons and glial cells). The IGFBP3 protein is primarily produced and secreted by the liver and is the major carrier of insulin-like growth factors 1 and 2 (IGF1, IGF2) in the blood. The resulting IGFBP3-IGF complex is typically taken up by cells through IGF receptor 1 to produce intracellular effects <xref ref-type="bibr" rid="pone.0004254-Lee2">&#x0005b;26&#x0005d;</xref>. In this context, uptake of IGFBP3 by brain cells could render them immunoreactive without accompanying gene expression. We found that CSF levels of IGFBP3 were high, suggesting significant translocation from serum into brain extracellular fluid. Other explanations could involve antibody specificity issues and relative differences in abundance between protein and mRNA in different cells. Induction of <italic>IGFBP3</italic> expression can occur in neurons and glial cells under various conditions, for example hypoxia <xref ref-type="bibr" rid="pone.0004254-Beilharz1">&#x0005b;27&#x0005d;</xref>, and this might also cause differences between humans and mice.</p><p>What function could IGFBP3 have in hypocretin producing cells with regard to narcolepsy? As the protein is co-localized with HCRT, IGFBP3 could have been an autoantigen involved in the hypothesized autoimmune attack directed against the HCRT neurons. We found no evidence for such autoantibodies in human sera and CSF, however. IGFBP3 levels were similar in CSF and serum of narcolepsy versus controls, and it is abundant in various human brain cells, possibly reflecting cellular uptake of circulating IGFBP3. These make it an unlikely candidate in directing an autoimmune process specifically toward HCRT neurons.</p><p>Even if not directly involved as an autoantigen in causing narcolepsy, IGFBP3 is still an interesting candidate as it plays key roles in regulating cell proliferation and apoptosis <xref ref-type="bibr" rid="pone.0004254-Fang1">&#x0005b;28&#x0005d;</xref>. The interaction of IGFBP3 with IGFs is generally believed to have primarily pro-growth effects by favoring target availability of IGF, but growth-inhibiting effects have also been noted. IGFBP3 is also reported to have proapoptotic properties independent of IGF-binding. For example, IGFBP3 expression in cancer cells and in the circulation is associated with less malignant growth and decreased cancer risk in breast <xref ref-type="bibr" rid="pone.0004254-Kim1">&#x0005b;29&#x0005d;</xref>, prostate <xref ref-type="bibr" rid="pone.0004254-Bhattacharyya1">&#x0005b;30&#x0005d;</xref> and other cancers <xref ref-type="bibr" rid="pone.0004254-Santer1">&#x0005b;31&#x0005d;</xref>. Of note, the proapoptotic effects commence with IGFBP3 translocation into the nucleus and binding of the retinoid-X-receptor-&#x003b1; (RXR&#x003b1;), with subsequent mobilization of the RXR&#x003b1; binding partner Nur77 from the nucleus to mitochondria, an event followed by caspase activation and apoptosis <xref ref-type="bibr" rid="pone.0004254-Lee1">&#x0005b;21&#x0005d;</xref>. We found no intranuclear IGFBP3 staining in human hypocretin cells (<xref ref-type="fig" rid="pone-0004254-g002">Fig 2 D,E</xref>), suggesting no proapoptotic effects in surviving hypocretin cells.</p><p>Recently however, proapoptotic effects of IGFBP3 independent of nuclear translocation and protein secretion have been demonstrated, suggesting additional cytoplasmic pathways also promote apoptosis <xref ref-type="bibr" rid="pone.0004254-Bhattacharyya1">&#x0005b;30&#x0005d;</xref>. It is thus possible that IGFBP3 produced within hypocretin cells would not be bound to IGFs, potentially increasing vulnerability to proapoptotic processes. Indeed, hypocretin neurons in slice cultures are more sensitive than neighboring cells to NMDA receptor-mediated injury <xref ref-type="bibr" rid="pone.0004254-Katsuki1">&#x0005b;32&#x0005d;</xref>. To test the hypothesis that excessive IGFBP3 in hypocretin cells contributes to this cell death, we crossed <italic>Hcrt</italic>-ataxin-3 transgenic mice (animals with targeted cell death 2&#x02013;4 weeks after birth) with transgenic mice overexpressing human IGFBP3 (<italic>hIGFBP3</italic>), but found no effects on the speed of hypocretin cell death. The lack of effects of IGFBP3 on cell death in this model might be due to the differences in circulating <italic>vs</italic> hypocretin cell specific IGFBP3 overexpression, or to lack of an IGFBP3 effect in the context of ataxin-induced cell degeneration, but is consistent with the notion that IGFBP3 may be proapoptotic only in specific circumstances, such as cancerous cells.</p><p>The results above do not support the involvement of IGFBP3 in causing hypocretin cell death in narcolepsy. We therefore next explored whether IGFBP3 modulates hypocretin transmission, with complementary <italic>in vitro</italic> and <italic>in vivo</italic> functional studies using <italic>hIGFBP3</italic> transgenic mice. We found that increased IGFBP3 decreases both hypocretin mRNA, and hypocretin peptide content in hypothalamus and target areas (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3A&#x02013;C</xref>). Although these effects could be indirectly mediated by minor endocrine abnormalities in these animals, for example hyperglycemia <xref ref-type="bibr" rid="pone.0004254-Silha2">&#x0005b;33&#x0005d;</xref>, the <italic>in vitro</italic> findings that IGFBP3 expression suppresses <italic>HCRT</italic> promotor activity (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3E</xref>) and that the functional IGFBP3 polymorphism rs2854744 is associated with reduced hypocretin transmission, observed as lower levels of Hcrt-1 in human CSF (<xref ref-type="fig" rid="pone-0004254-g003">Fig. 3F</xref>), makes this hypothesis unlikely. Overexpression of <italic>hmutIGFBP3</italic>, a mutant form that does not bind IGF, also reduces hypocretin peptide content in brainstem but not in hypothalamus suggesting both IGF dependent and independent effects on hypocretin transmission. Hypocretin transmission was normal in <italic>Igfbp3</italic> knockout mice, potentially reflecting functional redundancy among the 7 known IGFBP family members.</p><p>Increased IGFBP3 expression (which was stable across the 24 hrs) was shown to have functional effects on sleep, as <italic>hIGFBP3</italic> transgenic mice slept significantly more prior to light onset. It is notable that the effect was primarily observed at the end of the active period. As hypocretin release is highest at this time of the day (equivalent to the evening in humans), higher IGFBP3 levels may affect hypocretin transmission only at times of highest demand, through the reduction of releasable peptide stores in terminals.</p><p>IGFBP3 and IGF serum levels are highest around puberty, and drop thereafter <xref ref-type="bibr" rid="pone.0004254-Bunn1">&#x0005b;16&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004254-Carskadon1">&#x0005b;34&#x0005d;</xref>. It is thus interesting to speculate that increased sleepiness during puberty could coincide with peak IGFBP3 levels. Most work to date has focused on the studies of Growth Hormone, the primary determinant of IGF, while the effects of IGF on sleep seem complex <xref ref-type="bibr" rid="pone.0004254-Schneider1">&#x0005b;35&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004254-Obal1">&#x0005b;36&#x0005d;</xref>. Additional investigations of the chronic effects of IGFs and IGFBP3 on sleep changes around puberty are needed <xref ref-type="bibr" rid="pone.0004254-Carskadon1">&#x0005b;34&#x0005d;</xref>. IGFBP3, together with IGF, is to be added to the growing list of metabolic indicators that have been reported to regulate hypocretin activity.</p><p>In summary, this study exemplifies the successful use of human postmortem brain for microarray analysis of human neuropathology. The analysis not only confirmed known genes colocalized with hypocretin cells but also identified a new candidate with functional relevance to hypocretin cell physiology and sleep regulation. This factor, IGFBP3, is only expressed at high levels in a few neuronal cell groups besides hypocretin cells, and regulates hypocretin transcription. We hypothesize that increased IGFBP3 amount in HCRT cells decreases HCRT production and reduces wake under physiological conditions. When expression exceeds a specific threshold however, it may initiate hypocretin cell death and cause narcolepsy.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Human studies</title><sec id="s4a1"><title>Human samples</title><p>All blood and DNA samples were of Caucasian origin. Narcolepsy and control brain donors were primarily recruited through the Stanford narcolepsy brain donation program and the Stanford Brain Bank. Samples from 9 narcoleptic patients (89&#x00025; Caucasian) and 14 Caucasian controls were dissected. Six narcolepsy and 11 control samples were analyzed after passing quality control (<xref ref-type="table" rid="pone-0004254-t001">Table 1</xref>). Patients were all HLA <italic>DQB1&#x0002a;0602</italic> positive with cataplexy. Sera from 11 narcolepsy and 11 controls, CSF from 27 narcolepsy and 35 controls were also used for IGFBP3 measurements. DNA samples from 130 parent-child trios (proband and parents), and 252 individuals with available CSF hypocretin level values in the control range, were obtained and used. Informed consent was obtained in accordance with Stanford human subjects policy and the principles of the Declaration of Helsinki.</p></sec><sec id="s4a2"><title>Brain dissection</title><p>Four brain regions were dissected: posterior and anterior hypothalamus, LC and diagonal band of Broca. Coronal sections (0.9 mm) of hypothalamus and diagonal band, and transaxial brainstem sections were cut from frozen blocks, mounted, and stored at &#x02212;80&#x000b0;C. Digital photographs of the blocks were used for orientation and identification of target regions. The location of hypothalamic structures and the diagonal band were determined using human atlas coordinates <xref ref-type="bibr" rid="pone.0004254-Mai1">&#x0005b;37&#x0005d;</xref>. The LC was identified by atlas location <xref ref-type="bibr" rid="pone.0004254-Paxinos1">&#x0005b;38&#x0005d;</xref> and coloration.</p><p>Posterior hypothalamic samples were collected from the mammillary body (atlas fig.32, optic chiasm &#x0002b;13 mm) to the level where the fornix enters the hypothalamus (fig. 25, optic chiasm &#x0002b;4 mm). Anterior hypothalamic samples were collected from this level (fig. 24, optic chiasm &#x0002b;3 mm) to the optic chiasm (fig. 19, optic chiasm &#x02212;2 mm). Diagonal band areas closely surrounded the anterior hypothalamus in the same planes. Hypothalamic and diagonal band samples were dissected by scalpel, LC samples were collected with a 1.2 mm Palkovits punch (Stoelting Co., Wood Dale, IL).</p></sec><sec id="s4a3"><title>RNA isolation and Array Hybridization</title><p>Biotinylated cDNA synthesized from total RNA was hybridized to microarrays (HG-U133 A and B, Affymetrix, Santa Clara, CA) according to manufacturer protocols (Genechip manual, Affymetrix). Fluorescent array images were scanned (Affymetrix GeneArray 2500 or GeneChip 3000 scanner) and analyzed with global scaling, adjusting mean target intensity to 500 for all probe sets (Affymetrix MAS 5.0 software).</p></sec><sec id="s4a4"><title>Quality control and sample comparisons</title><p>The pH of each sample was measured (homogenate of a 10&#x000d7; dilution of 0.5 g of temporal cortex or striatum in water). Samples with pH&#x02264;6.5 were excluded <xref ref-type="bibr" rid="pone.0004254-Tomita1">&#x0005b;39&#x0005d;</xref>. Integrity of extracted RNA was verified by RNA nano LabChips on a 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Samples with a 28S/18S ratio below 0.5 were discarded (median ratio 0.81). Microarray data was also used to estimate RNA quality (ratio of <italic>GAPDH</italic> 3&#x02032; over 5&#x02032; probe hybridization). Samples with a ratio over 8 were excluded (median ratio 2.3). Postmortem interval had less effect on RNA quality and subjects were included independent of interval (median 7 hrs, all below 48 hrs).</p><p>We compared regional transcript abundance in 11 control brains (74.0&#x000b1;13.0 years old, PMI: 14.1&#x000b1;17.0 hr, 63.6&#x00025; male, 36.4&#x00025; HLA <italic>DQB1&#x0002a;0602</italic> positive). Sample size for brain regions (varied due to availability and sample quality) included 8 posterior hypothalami, 6 anterior hypothalami, 7 diagonal bands and 4 LCs. We compared posterior hypothalami of 6 narcoleptic patients (68.8&#x000b1;12.3 years old, PMI 15.7&#x000b1;16.3 hr, 33.3&#x00025; male, all <italic>DQB1&#x0002a;0602</italic> positive) and 8 controls (73.0&#x000b1;13.0 years old, PMI 11.8&#x000b1;15.0 hr, 62.5&#x00025; male, 37.5&#x00025; <italic>DQB1&#x0002a;0602</italic> positive) for the A chip, and 5 narcolepsy and 7 control samples for the B chip (<xref ref-type="table" rid="pone-0004254-t001">Table 1</xref>). Overall mean age, PMI and sex did not differ significantly.</p></sec><sec id="s4a5"><title>Statistical analysis of array data</title><p>MAS 5.0 was used for signal calculation and present/absent determination combined with SAM ranking analysis to identify significantly up/down regulated genes. Data from the A and B chips were analyzed separately. Probes with an absent or marginal call in more than 90&#x00025; of samples were omitted as were array tags linked to multiple genes, and only the highest SAM ranked probe for a gene was included. Filtering eliminated 41&#x00025; and 53&#x00025; of the transcripts from the A and B chips in the narcolepsy <italic>vs</italic> control comparison. Results were reported as SAM rankings, fold changes in average expression levels, and Mann-Whitney U-test <italic>p</italic>-values. The top 15 SAM upregulated genes were used for comparisons across brain regions. Genes upregulated in two of three comparisons were reported. For the comparison of posterior hypothalamus between narcolepsy and control, the top 100 SAM up or down regulated candidates were selected and sorted based on fold changes: those above 2.5 or below 0.4 fold change were studied further.</p></sec><sec id="s4a6"><title>Quantitative Reverse Transcriptase PCR</title><p>Candidate transcripts were studied by QRT-PCR (ABI 7300 system, Applied Biosystems, Foster City, CA). cDNA was synthesized from total RNA using Superscript III Reverse Transcriptase and random hexamer.(Invitrogen, Carlsbad, CA). Geometric means of &#x003b2;-actin and &#x003b2;2-microglobulin were used for normalization (geNorm analysis) <xref ref-type="bibr" rid="pone.0004254-Vandesompele1">&#x0005b;40&#x0005d;</xref>. After performing QRT-PCR for selected genes in parallel with &#x003b2;-actin and &#x003b2;2-microglobulin, relative expression quantity was calculated. Genes were considered validated when the mean fold change was more than 1.5 and Mann-Whitney U-test indicated statistical significance (p&#x0003c;0.05). Expression differences for <italic>CART</italic><xref ref-type="bibr" rid="pone.0004254-Broberger1">&#x0005b;41&#x0005d;</xref>, <italic>GAL</italic><xref ref-type="bibr" rid="pone.0004254-Hakansson1">&#x0005b;42&#x0005d;</xref>, <italic>PDYN</italic><xref ref-type="bibr" rid="pone.0004254-Chou1">&#x0005b;9&#x0005d;</xref> and <italic>NPTX2</italic><xref ref-type="bibr" rid="pone.0004254-Reti1">&#x0005b;10&#x0005d;</xref> were also verified.</p></sec><sec id="s4a7"><title>Human brain immunohistochemistry</title><p>Six hypothalami (4 control, 2 narcolepsy) were fixed in 4&#x00025; paraformaldehyde (PFA, pH 7.3), cryoprotected and sectioned coronally to obtain a series of 24 sections (40 &#x000b5;m). The following steps were performed at 4&#x000b0;C interspersed with washes. Sections were (I) treated with 0.3&#x00025; H<sub>2</sub>O<sub>2</sub>, (II) post-fixed with 4&#x00025; PFA, (III) blocked in 1.5&#x00025; horse serum, (IV) incubated with mouse anti-HCRT monoclonal antibody (1&#x02236;250) <xref ref-type="bibr" rid="pone.0004254-Taheri1">&#x0005b;43&#x0005d;</xref> or a monoclonal anti-NeuN antibody (1&#x02236;50,000;Millipore, Billerica, MA) (V) incubated with biotinylated horse anti-mouse IgG (1&#x02236;200; Vector Laboratories, Burlingame, CA), (VI) alkaline phosphatase (AP) conjugated ABC (1&#x02236;100; Vector), and (VII) VectaRed AP-substrate (1&#x02236;50; Vector) in 0.1 M Tris-HCl (pH 8.4) until satisfactory staining was obtained. Sections were then (VIII) incubated in 1.5&#x00025; rabbit serum, (IX) goat anti-IGFBP3 antiserum (1&#x02236;250; AF675 R&#x00026;D Systems, Minneapolis, MN), (X) biotinylated rabbit anti-goat IgG (1&#x02236;200, Vector), (XI) ABC reagent (1&#x02236;100; Vector), (XII) biotinyl-tyramide (1&#x02236;500; PerkinElmer) with 0.03&#x00025; H<sub>2</sub>O<sub>2</sub>, and (XIII) Qdot 525 streptavidin conjugate (1&#x02236;100;Invitrogen) in borate buffer (pH 8.5). Sections were mounted and analyzed under a fluorescence microscope equipped with a CCD camera: images were digitally merged to visualize the colocalization of signals.</p></sec><sec id="s4a8"><title>Evaluation of hypocretin and IGFBP3 levels, antibodies and IGFBP3 genotyping</title><p>CSF and serum IGFBP3 levels were measured in duplicate using a total ELISA kit (DSL-10-6600; Diagnostic Systems Laboratories, Webster, TX) according to the manufacturer's protocol. Average intra-assay coefficients of variation were 2.5&#x00025;. CSF hypocretin-1 levels were measured using a radioimmunoassay as reported previously <xref ref-type="bibr" rid="pone.0004254-Mignot2">&#x0005b;2&#x0005d;</xref>. We tested CSF of 27 narcolepsy and 35 matched controls, and serum from 11 narcolepsy and 11 controls.</p><p>Full length <italic>IGFBP3</italic> cDNA (EcoR1-ApaI fragment, clone 5287665, Invitrogen) was subcloned into pCMV-Tag3 and transfected into COS-1 cells (Lipofectamine 2000, Invitrogen). Protein was extracted from cells and culture medium by standard methods (RIPA buffer, and protocol Sigma, St. Louis, MO).</p><p>Protein extracts were run on 10&#x00025; SDS-PAGE gels, transferred onto nitrocellulose, and incubated with anti-human IGFBP3 polyclonal antiserum (1&#x02236;200; Santa Cruz Biotechnology, Santa Cruz, CA), followed by horseradish peroxidase (HRP)-conjugated donkey anti-goat IgG (1&#x02236;4000) and then detected with Supersignal West Pico chemiluminescence reagent (ThermoFisher, Wyman, MA), revealing the 42 kDa IGFBP3 band. Similar membranes were used to detect anti IGFBP3 antibodies in human sera. Membranes were incubated with serum (1&#x02236;200) followed by HRP-donkey anti-human antiserum (1&#x02236;5000), and chemiluminescent detection. Twenty two narcolepsy and 20 control samples were tested.</p><p>The single base pair polymorphism in the <italic>IGFBP3</italic> promoter (rs2854744, &#x02212;202 A/C) was genotyped in 130 Caucasian narcolepsy-cataplexy trios and 262 adult Caucasian subjects (54&#x00025; females; mean age 35.8&#x000b1;0.8 years) using established methods <xref ref-type="bibr" rid="pone.0004254-Jernstrom1">&#x0005b;17&#x0005d;</xref>.</p></sec></sec><sec id="s4b"><title>Mouse studies</title><sec id="s4b1"><title>Animals and tissue preparation</title><p>Five different mouse lines were used: hypocretin-ataxin-3 transgenic mice lacking hypocretin neurons (<italic>Hcrt</italic>-ataxin-3: C57BL/6J background), preprohypocretin knockout mice (<italic>Hcrt</italic> KO: C57BL/6J background), IGFBP3 knockout mice (<italic>mIgfbp3</italic> KO: C57BL/6J background) (courtesy of Dr JE Pintar, University of Medicine and Dentistry of New Jersey, Piscataway, NJ) <xref ref-type="bibr" rid="pone.0004254-Ning1">&#x0005b;18&#x0005d;</xref>, transgenic mice overexpressing human IGFBP3 cDNA (<italic>hIGFBP3</italic> transgenic: CD1 background), transgenic mice overexpressing the Gly56/Gly80/Gly81 mutated form of human IGFBP3 which lacks IGF binding (<italic>hmutIGFBP3</italic> transgenic: CD1 background) (courtesy of Dr. LJ Murphy, University of Manitoba, Winnipeg, Canada) <xref ref-type="bibr" rid="pone.0004254-Modric1">&#x0005b;19&#x0005d;</xref>. The latter two mouse strains allow differentiation between IGF-bound and IGF-independent effects of the protein. Two human <italic>IGFBP3</italic> genes were driven by the same mouse phosphoglycerate kinase I promotor, and were used to distinguish the effect of IGF binding. In all transgenic comparisons, age matched mice of the corresponding genetic background, usually littermates, were used at all times. Mice were maintained under controlled temperature (21&#x000b1;1&#x000b0;C) and 12 h:12 h light-dark cycle with free access to food and water. The entire study was approved and conducted in accordance with the guidelines of Stanford's Administrative Panel for Laboratory Animal Care.</p><p>For neuroanatomical studies, mice were euthanized (pentobarbital) and perfused transcardially with saline followed by 50 ml 10&#x00025; formalin (pH 7.4). Brains were fixed in 10&#x00025; formalin, and equilibrated with 20&#x00025; sucrose/0.5&#x00025; formalin. Coronal slices (30 &#x000b5;m) containing the whole hypothalamus were sectioned into a 1&#x02236;5 series and mounted.</p></sec><sec id="s4b2"><title>Mouse microarray experiments</title><p>Groups of 30 wild type and 30 ataxin-3 transgenic mice were used. Perifornical hypothalamic 0.5 mm Palkovits punches encompassing the hypocretin field (<xref ref-type="supplementary-material" rid="pone.0004254.s003">Fig. S1</xref>) were collected at ZT 22. Biotinylated cRNA was synthesized from total RNA and hybridized to Affymetrix Mouse 430 microarrays and scanned fluorescent array images were analyzed with GeneChip Operating Software (Affymetrix)</p></sec><sec id="s4b3"><title><italic>In situ</italic> hybridization for candidate genes</title><p><italic>In situ</italic> hybridization was performed on 6&#x02013;10 week male C57BL/6J mice. Mouse cDNA IMAGE clones (<xref ref-type="table" rid="pone-0004254-t002">Table 2</xref>; Invitrogen) were sequence verified (Bionexus, Oakland, CA) and used. Plasmid DNA was linearized and transcribed with T7, T3 or SP6 polymerases (Promega, Madison, WI) and <sup>35</sup>S-UTP (Amersham BioSciences, Piscataway, NJ) or digoxigenin-UTP (Roche Diagnostics, Indianapolis, IN) by standard methods.</p><p>Probes were diluted in standard hybridization buffer to 3&#x000d7;10<sup>6</sup> counts per 125 &#x000b5;l. Sections were pretreated in citrate buffer (pH 6.0), and hybridized with probe at 54&#x000b0;C, followed by RNase A treatment and stringent washes (2&#x000d7;SSC at 50&#x000b0;C; 0.2&#x000d7;SSC, 55&#x000b0;C; 0.2&#x000d7;SSC, 65&#x000b0;C), dehydrated and exposed to films for 1&#x02013;40 days.</p></sec><sec id="s4b4"><title>In situ hybridization of IGFBP3 and HCRT immunostaining</title><p>Digoxigenin-labeled probe (1&#x02236;500) was used in hybridizations as described. Sections were treated with 3&#x00025; sheep serum/0.1&#x00025; Triton X-100, and incubated overnight with alkaline phosphatase-conjugated sheep anti-digoxigenin antibodies (1&#x02236;5000; Roche). Endogenous alkaline phosphatase was blocked (levamisole) and hybridization was visualized by incubation in 0.3 mg/ml NBT(nitroblue tetrazolium) and 0.2 mg/ml BCIP(5-bromo,4-choloro,3-indolylphosphate).</p><p>Sections with satisfactory <italic>IGFBP3</italic> signal were immunostained with highly specific rabbit anti-HCRT-1 antiserum (1&#x02236;4000; made with human HCRT-1 as immunogen). Slides were washed and incubated with (I) biotinylated goat anti-rabbit IgG (1&#x02236;500; Jackson Immunoresearch, West Grove, PA), (II) ABC complex (1&#x02236;1000; Vector), (III) biotinylated tyramide diluted 1&#x02236;50 in amplification buffer (Perkin Elmer), (IV) Alexa Fluor-conjugated streptavidin (1&#x02236;200;Invitrogen).</p><p>To stain and count hypocretin cell populations, successive sections encompassing the entire hypocretin field were stained using an anti HCRT-1 antiserum as described above. Cells were counted without corrections and blind of genotype status.</p></sec><sec id="s4b5"><title>Hypocretin-1 radioimmunoassay</title><p>Frozen brain tissue of animals sacrificed at Zeitbeger time ZT2&#x02013;ZT3 were extracted with 1 mL of 0.5 M acetic acid and boiled in water bath for 15 minutes. Samples were cooled on ice and centrifuged at 5000&#x000d7;g for 10 minutes. Protein concentration in the supernatant was measured using the Bradford method (Bio-Rad Laboratories, Hercules, CA). The supernatants were dried overnight at 50&#x000b0;C and reconstituted in RIA buffer for radioimmunoassay using a commercially available <sup>125</sup>I RIA kit (Phoenix Pharmaceuticals, Belmont, CA) as described <xref ref-type="bibr" rid="pone.0004254-Lin2">&#x0005b;44&#x0005d;</xref>. The hypocretin contents were corrected against protein concentrations.</p></sec><sec id="s4b6"><title>Preprohypocretin, murine/human IGFBP3 and MCH mRNA quantification</title><p>Total RNA from mice hypothalamic regions with RNA extraction reagents (Qiagen, Valencia, CA) and synthesized cDNA was subjected to TaqMan real time PCR analysis to measure relative preprohypocretin, murine/human IGFBP3, and MCH expression levels in parallel with &#x000df;-actin, hypoxanthine-guanine phosphoribosyltransferase (HPRT) and GAPDH as internal controls. HPRT was chosen for data normalization due to its stable expression across the genotypes.</p></sec><sec id="s4b7"><title>Mouse sleep recording and analysis</title><p>Nine wild type (WT) and 13 transgenic (TG) mice (age 3&#x02013;6 months) were implanted under isofluorane anesthesia with telemetry transmitters (ETA-F20, 3.9 g weight, Data Science International, St. Paul, MN) capable of acquiring and sending electroencephalograph (EEG), temperature, and movement data. The two EEG electrodes were secured with dental cement at the following coordinates: anterior/posterior from bregma (AP) 1.5 mm, lateral (ML) 1.5 mm and AP &#x02212;3.5 mm, ML &#x02212;3 mm. An analgesic (5 mg/kg Carprofen) and antibiotics (5 mg/kg/day enrofloxacin) was given subcutaneously. Mice were allowed to fully recover for a minimum of two weeks before the experiments. Animals were recorded for a 48-hour period, with the first 24 h undisturbed, followed by 6 h wake extension by gentle handling, and 18 h undisturbed recovery. EEG was sampled at 250 Hz, and the other parameters were sampled at 50 Hz using DataQuest A.R.T. 3.1 (Data Science International, St. Paul, MN). Recordings were scored manually in 10 second epochs using SleepSign (Kissei America, Irvine, CA) according to the method developed previously <xref ref-type="bibr" rid="pone.0004254-Zhang1">&#x0005b;45&#x0005d;</xref>.</p></sec></sec><sec id="s4c"><title>Hypocretin promoter studies</title><sec id="s4c1"><title>Cell culture</title><p>HeLa (human cervical carcinoma), SF126 (human glioblastoma), and Becker (human astrocytoma) cells were grown in Dulbecco's modified Eagle's medium (DMEM; GIBCO, Grand Island, NY) supplemented with 10&#x00025; fetal bovine serum (GIBCO),.and SH-SY5Y (human neuroblastoma) cells were grown in DMEM/F12 supplemented with 5&#x00025; horse serum (GIBCO), at 37&#x000b0;C and 5&#x00025; CO<sub>2</sub>.</p></sec><sec id="s4c2"><title>Reporter plasmids</title><p>The pGL3-basic plasmid (Promega) encoding the firefly luciferase gene was used for the promoter activity assessment with introduced sequence and the pRL-TK plasmid (Promega) encoding Renilla luciferase was used as internal control for transfection efficiency. The plasmid 3.2 kb Hcrt/pGL3 was constructed by cloning the HCRT promoter sequence at &#x02212;3278/&#x0002b;87 <xref ref-type="bibr" rid="pone.0004254-Sakurai2">&#x0005b;46&#x0005d;</xref> into upstream of the firefly luciferase gene in pGL3-Basic plasmid; <named-content content-type="gene">5&#x02032;- ccgctcgagGGTGTCTGGCGCTCAGGGTG-3&#x02032;</named-content> (corresponds to the first exon sequence just before the translation initiator ATG of human prepro-Hcrt gene, and <named-content content-type="gene">5&#x02032;- CGACGCGTGGATCCAGATGCCTCTGAATAG-3&#x02032;</named-content> (&#x02212;3278) were used.</p></sec><sec id="s4c3"><title>Transient transfection</title><p>Cells were seeded at a 250,000 per well in 24-well cell culture plate coated with collagen type I (BD Biosciences, Bedford MA) one day before transfection. Cells were co-transfected with three types of plasmid mixed in the following amount per well with FuGENE 6 Transfection Reagent (Roche): 200 ng firefly luciferase-encoding reporter plasmid (pGL3-basic or 3.2 kb Hcrt/pGL3), 20 ng Renilla luciferase-encoding internal control reporter plasmid (pRL-TK), and 200 ng expression vector (pCMV-Tag3 as mock or IGFBP3/pCMV-Tag3).</p></sec><sec id="s4c4"><title>Luciferase activity measurements</title><p>At 24 h after transfection, cells were washed and lysed with 100 &#x000b5;L passive lysis buffer (Promega). Activities of two luciferases encoded by reporter plasmids and internal control plasmids were measured sequentially twice using the Dual-Luciferase Reporter assay reagents (Promega) and PLATE CHAMELEON multilabel platereader (HIDEX, Finland) according to the manufacturer's protocol. Relative luciferase activity (RLA) was determined by FLU value divided by RLU value. All RLA values were further standardized by the reference RLA value for pGL3-basic plasmid with pCMV-Tag3 vector (mock) as 1.0.</p></sec></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0004254.s001"><label>Table S1</label><caption><p>Cross-regional comparison of transcript abundance in selected human brain regions. Comparison of microarray expression data across 4 brain regions in control subjects The listed genes have enriched expression in the indicated region, as compared to the other regions. For example, PMCH gene expression was increased 73.8 fold in the posterior hypothalamus when compared to the anterior hypothalamus and ranked #1 using the SAM analysis. Similarly, PMCH gene expression in the posterior hypothalamus ranked first versus the diagonal band sample (3.3 fold change), and the LC (275.1 fold change). Only genes enriched in one region versus at least two other regions are listed (see <xref ref-type="sec" rid="s4">methods</xref>).</p><p>(0.13 MB DOC)</p></caption><media xlink:href="pone.0004254.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004254.s002"><label>Table S2</label><caption><p>Overall sleep parameters in mice overexpressing human IGFBP3 (TG) versus wild type littermates (WT)Although total wake is decreased in TG mice, the difference is not statistically significant. Hour by hour analysis revealed that decreased wake occurred prior to light onset (see <xref ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>).</p><p>(0.06 MB DOC)</p></caption><media xlink:href="pone.0004254.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004254.s003"><label>Figures S1</label><caption><p>Perifornical hypothalamic region dissected for microarray analysis in mice (A) and transcript abundance distribution plots correlating abundance in wild type versus ataxin-3 transgenic mice (B). (A) Immunocytochemistry of hypocretin in wild type (WT, top) and Hcrt-ataxin-3 transgenic mouse (bottom). The area collected using punches is outlined by a circle in wild type versus transgenic mice lacking most hypocretin cells. Transcript abundance distribution (B) in both genotypes is highly correlated, and hypocretin is one of the outliers (circled dot). For list of differentially regulated transcripts, see <xref ref-type="table" rid="pone-0004254-t003">Table 3</xref>.</p><p>(1.56 MB TIF)</p></caption><media xlink:href="pone.0004254.s003.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004254.s004"><label>Figure S2</label><caption><p>Locomotion (A) and temperature (B) in wild type (WT) versus hIGFBP3 transgenic mice (Tg). Note decreased temperature and locomotion at the end of the active period in hIGFBP3 transgenic mice, mirroring changes in sleep depicted in <xref ref-type="fig" rid="pone-0004254-g004">Fig. 4</xref>.</p><p>(5.70 MB TIF)</p></caption><media xlink:href="pone.0004254.s004.tif" mimetype="image" mime-subtype="tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0004254-Mignot1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><etal/></person-group><year>2001</year><article-title>Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups.</article-title><source>Am J Hum Genet</source><volume>68</volume><fpage>686</fpage><lpage>699</lpage><pub-id pub-id-type="pmid">11179016</pub-id></citation></ref><ref id="pone.0004254-Mignot2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mignot</surname><given-names>E</given-names></name><name><surname>Lammers</surname><given-names>GJ</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Okun</surname><given-names>M</given-names></name><name><surname>Nevsimalova</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.</article-title><source>Arch Neurol</source><volume>59</volume><fpage>1553</fpage><lpage>1562</lpage><pub-id pub-id-type="pmid">12374492</pub-id></citation></ref><ref id="pone.0004254-Sakurai1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Amemiya</surname><given-names>A</given-names></name><name><surname>Ishii</surname><given-names>M</given-names></name><name><surname>Matsuzaki</surname><given-names>I</given-names></name><name><surname>Chemelli</surname><given-names>RM</given-names></name><etal/></person-group><year>1998</year><article-title>Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.</article-title><source>Cell</source><volume>92</volume><fpage>1 page following 696</fpage><pub-id pub-id-type="pmid">9527442</pub-id></citation></ref><ref id="pone.0004254-Chemelli1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chemelli</surname><given-names>RM</given-names></name><name><surname>Willie</surname><given-names>JT</given-names></name><name><surname>Sinton</surname><given-names>CM</given-names></name><name><surname>Elmquist</surname><given-names>JK</given-names></name><name><surname>Scammell</surname><given-names>T</given-names></name><etal/></person-group><year>1999</year><article-title>Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.</article-title><source>Cell</source><volume>98</volume><fpage>437</fpage><lpage>451</lpage><pub-id pub-id-type="pmid">10481909</pub-id></citation></ref><ref id="pone.0004254-Lin1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Faraco</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Kadotani</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><etal/></person-group><year>1999</year><article-title>The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.</article-title><source>Cell</source><volume>98</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">10458611</pub-id></citation></ref><ref id="pone.0004254-Hara1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hara</surname><given-names>J</given-names></name><name><surname>Beuckmann</surname><given-names>CT</given-names></name><name><surname>Nambu</surname><given-names>T</given-names></name><name><surname>Willie</surname><given-names>JT</given-names></name><name><surname>Chemelli</surname><given-names>RM</given-names></name><etal/></person-group><year>2001</year><article-title>Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.</article-title><source>Neuron</source><volume>30</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">11394998</pub-id></citation></ref><ref id="pone.0004254-Peyron1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peyron</surname><given-names>C</given-names></name><name><surname>Faraco</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>W</given-names></name><name><surname>Ripley</surname><given-names>B</given-names></name><name><surname>Overeem</surname><given-names>S</given-names></name><etal/></person-group><year>2000</year><article-title>A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.</article-title><source>Nat Med</source><volume>6</volume><fpage>991</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">10973318</pub-id></citation></ref><ref id="pone.0004254-Thannickal1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>TC</given-names></name><name><surname>Moore</surname><given-names>RY</given-names></name><name><surname>Nienhuis</surname><given-names>R</given-names></name><name><surname>Ramanathan</surname><given-names>L</given-names></name><name><surname>Gulyani</surname><given-names>S</given-names></name><etal/></person-group><year>2000</year><article-title>Reduced number of hypocretin neurons in human narcolepsy.</article-title><source>Neuron</source><volume>27</volume><fpage>469</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">11055430</pub-id></citation></ref><ref id="pone.0004254-Chou1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>TC</given-names></name><name><surname>Lee</surname><given-names>CE</given-names></name><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Elmquist</surname><given-names>JK</given-names></name><name><surname>Hara</surname><given-names>J</given-names></name><etal/></person-group><year>2001</year><article-title>Orexin (hypocretin) neurons contain dynorphin.</article-title><source>J Neurosci</source><volume>21</volume><fpage>RC168</fpage><pub-id pub-id-type="pmid">11567079</pub-id></citation></ref><ref id="pone.0004254-Reti1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reti</surname><given-names>IM</given-names></name><name><surname>Reddy</surname><given-names>R</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Baraban</surname><given-names>JM</given-names></name></person-group><year>2002</year><article-title>Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons.</article-title><source>J Neurochem</source><volume>82</volume><fpage>1561</fpage><lpage>1565</lpage><pub-id pub-id-type="pmid">12354306</pub-id></citation></ref><ref id="pone.0004254-Blouin1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blouin</surname><given-names>AM</given-names></name><name><surname>Thannickal</surname><given-names>TC</given-names></name><name><surname>Worley</surname><given-names>PF</given-names></name><name><surname>Baraban</surname><given-names>JM</given-names></name><name><surname>Reti</surname><given-names>IM</given-names></name><etal/></person-group><year>2005</year><article-title>Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy.</article-title><source>Neurology</source><volume>65</volume><fpage>1189</fpage><lpage>1192</lpage><pub-id pub-id-type="pmid">16135770</pub-id></citation></ref><ref id="pone.0004254-Crocker1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crocker</surname><given-names>A</given-names></name><name><surname>Espana</surname><given-names>RA</given-names></name><name><surname>Papadopoulou</surname><given-names>M</given-names></name><name><surname>Saper</surname><given-names>CB</given-names></name><name><surname>Faraco</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.</article-title><source>Neurology</source><volume>65</volume><fpage>1184</fpage><lpage>1188</lpage><pub-id pub-id-type="pmid">16247044</pub-id></citation></ref><ref id="pone.0004254-Thannickal2"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thannickal</surname><given-names>TC</given-names></name><name><surname>Siegel</surname><given-names>JM</given-names></name><name><surname>Nienhuis</surname><given-names>R</given-names></name><name><surname>Moore</surname><given-names>RY</given-names></name></person-group><year>2003</year><article-title>Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy.</article-title><source>Brain Pathol</source><volume>13</volume><fpage>340</fpage><lpage>351</lpage><pub-id pub-id-type="pmid">12946023</pub-id></citation></ref><ref id="pone.0004254-Scammell1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scammell</surname><given-names>TE</given-names></name></person-group><year>2006</year><article-title>The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy.</article-title><source>Sleep</source><volume>29</volume><fpage>601</fpage><lpage>602</lpage><pub-id pub-id-type="pmid">16774147</pub-id></citation></ref><ref id="pone.0004254-Tusher1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tusher</surname><given-names>VG</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name><name><surname>Chu</surname><given-names>G</given-names></name></person-group><year>2001</year><article-title>Significance analysis of microarrays applied to the ionizing radiation response.</article-title><source>Proc Natl Acad Sci U S A</source><volume>98</volume><fpage>5116</fpage><lpage>5121</lpage><pub-id pub-id-type="pmid">11309499</pub-id></citation></ref><ref id="pone.0004254-Bunn1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bunn</surname><given-names>RC</given-names></name><name><surname>King</surname><given-names>WD</given-names></name><name><surname>Winkler</surname><given-names>MK</given-names></name><name><surname>Fowlkes</surname><given-names>JL</given-names></name></person-group><year>2005</year><article-title>Early developmental changes in IGF-I, IGF-II, IGF binding protein-1, and IGF binding protein-3 concentration in the cerebrospinal fluid of children.</article-title><source>Pediatr Res</source><volume>58</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">15774848</pub-id></citation></ref><ref id="pone.0004254-Jernstrom1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jernstrom</surname><given-names>H</given-names></name><name><surname>Deal</surname><given-names>C</given-names></name><name><surname>Wilkin</surname><given-names>F</given-names></name><name><surname>Chu</surname><given-names>W</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><etal/></person-group><year>2001</year><article-title>Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women.</article-title><source>Cancer Epidemiol Biomarkers Prev</source><volume>10</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">11319179</pub-id></citation></ref><ref id="pone.0004254-Ning1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Schuller</surname><given-names>AG</given-names></name><name><surname>Bradshaw</surname><given-names>S</given-names></name><name><surname>Rotwein</surname><given-names>P</given-names></name><name><surname>Ludwig</surname><given-names>T</given-names></name><etal/></person-group><year>2006</year><article-title>Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5.</article-title><source>Mol Endocrinol</source><volume>20</volume><fpage>2173</fpage><lpage>2186</lpage><pub-id pub-id-type="pmid">16675541</pub-id></citation></ref><ref id="pone.0004254-Modric1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Modric</surname><given-names>T</given-names></name><name><surname>Silha</surname><given-names>JV</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Suwanichkul</surname><given-names>A</given-names></name><etal/></person-group><year>2001</year><article-title>Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice.</article-title><source>Endocrinology</source><volume>142</volume><fpage>1958</fpage><lpage>1967</lpage><pub-id pub-id-type="pmid">11316761</pub-id></citation></ref><ref id="pone.0004254-Silha1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silha</surname><given-names>JV</given-names></name><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Mishra</surname><given-names>S</given-names></name><name><surname>Leckstrom</surname><given-names>A</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><etal/></person-group><year>2005</year><article-title>Overexpression of gly56/gly80/gly81-mutant insulin-like growth factor-binding protein-3 in transgenic mice.</article-title><source>Endocrinology</source><volume>146</volume><fpage>1523</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">15550509</pub-id></citation></ref><ref id="pone.0004254-Lee1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>XK</given-names></name><etal/></person-group><year>2005</year><article-title>Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77.</article-title><source>J Biol Chem</source><volume>280</volume><fpage>16942</fpage><lpage>16948</lpage><pub-id pub-id-type="pmid">15731112</pub-id></citation></ref><ref id="pone.0004254-Franz1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franz</surname><given-names>H</given-names></name><name><surname>Ullmann</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>M</given-names></name><name><surname>Bahn</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Systematic analysis of gene expression in human brains before and after death.</article-title><source>Genome Biol</source><volume>6</volume><fpage>R112</fpage><pub-id pub-id-type="pmid">16420671</pub-id></citation></ref><ref id="pone.0004254-VogelHopker1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vogel-Hopker</surname><given-names>A</given-names></name><name><surname>Rohrer</surname><given-names>H</given-names></name></person-group><year>2002</year><article-title>The specification of noradrenergic locus coeruleus (LC) neurones depends on bone morphogenetic proteins (BMPs).</article-title><source>Development</source><volume>129</volume><fpage>983</fpage><lpage>991</lpage><pub-id pub-id-type="pmid">11861481</pub-id></citation></ref><ref id="pone.0004254-Mandel1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mandel</surname><given-names>S</given-names></name><name><surname>Grunblatt</surname><given-names>E</given-names></name><name><surname>Riederer</surname><given-names>P</given-names></name><name><surname>Amariglio</surname><given-names>N</given-names></name><name><surname>Jacob-Hirsch</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.</article-title><source>Ann N Y Acad Sci</source><volume>1053</volume><fpage>356</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">16179542</pub-id></citation></ref><ref id="pone.0004254-Coyle1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coyle</surname><given-names>AJ</given-names></name><name><surname>Lloyd</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Erikkson</surname><given-names>C</given-names></name><etal/></person-group><year>1999</year><article-title>Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses.</article-title><source>J Exp Med</source><volume>190</volume><fpage>895</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">10510079</pub-id></citation></ref><ref id="pone.0004254-Lee2"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Bang</surname><given-names>P</given-names></name><etal/></person-group><year>2004</year><article-title>Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>469</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">14576164</pub-id></citation></ref><ref id="pone.0004254-Beilharz1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beilharz</surname><given-names>EJ</given-names></name><name><surname>Russo</surname><given-names>VC</given-names></name><name><surname>Butler</surname><given-names>G</given-names></name><name><surname>Baker</surname><given-names>NL</given-names></name><name><surname>Connor</surname><given-names>B</given-names></name><etal/></person-group><year>1998</year><article-title>Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury.</article-title><source>Brain Res Mol Brain Res</source><volume>59</volume><fpage>119</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9729323</pub-id></citation></ref><ref id="pone.0004254-Fang1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>P</given-names></name><name><surname>Hwa</surname><given-names>V</given-names></name><name><surname>Rosenfeld</surname><given-names>R</given-names></name></person-group><year>2004</year><article-title>IGFBPs and cancer.</article-title><source>Novartis Found Symp</source><volume>262</volume><fpage>215</fpage><lpage>230</lpage><comment>discussion 230&#x02013;214, 265&#x02013;218</comment><pub-id pub-id-type="pmid">15562832</pub-id></citation></ref><ref id="pone.0004254-Kim1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Ingermann</surname><given-names>AR</given-names></name><name><surname>Tsubaki</surname><given-names>J</given-names></name><name><surname>Twigg</surname><given-names>SM</given-names></name><name><surname>Walker</surname><given-names>GE</given-names></name><etal/></person-group><year>2004</year><article-title>Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells.</article-title><source>Cancer Res</source><volume>64</volume><fpage>2229</fpage><lpage>2237</lpage><pub-id pub-id-type="pmid">15026367</pub-id></citation></ref><ref id="pone.0004254-Bhattacharyya1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>N</given-names></name><name><surname>Pechhold</surname><given-names>K</given-names></name><name><surname>Shahjee</surname><given-names>H</given-names></name><name><surname>Zappala</surname><given-names>G</given-names></name><name><surname>Elbi</surname><given-names>C</given-names></name><etal/></person-group><year>2006</year><article-title>Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus.</article-title><source>J Biol Chem</source><volume>281</volume><fpage>24588</fpage><lpage>24601</lpage><pub-id pub-id-type="pmid">16793770</pub-id></citation></ref><ref id="pone.0004254-Santer1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Santer</surname><given-names>FR</given-names></name><name><surname>Bacher</surname><given-names>N</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name><name><surname>Morandell</surname><given-names>D</given-names></name><name><surname>Ressler</surname><given-names>S</given-names></name><etal/></person-group><year>2006</year><article-title>Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis.</article-title><source>Cancer Res</source><volume>66</volume><fpage>3024</fpage><lpage>3033</lpage><pub-id pub-id-type="pmid">16540651</pub-id></citation></ref><ref id="pone.0004254-Katsuki1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katsuki</surname><given-names>H</given-names></name><name><surname>Akaike</surname><given-names>A</given-names></name></person-group><year>2004</year><article-title>Excitotoxic degeneration of hypothalamic orexin neurons in slice culture.</article-title><source>Neurobiol Dis</source><volume>15</volume><fpage>61</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">14751771</pub-id></citation></ref><ref id="pone.0004254-Silha2"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Silha</surname><given-names>JV</given-names></name><name><surname>Gui</surname><given-names>Y</given-names></name><name><surname>Murphy</surname><given-names>LJ</given-names></name></person-group><year>2002</year><article-title>Impaired glucose homeostasis in insulin-like growth factor-binding protein-3-transgenic mice.</article-title><source>Am J Physiol Endocrinol Metab</source><volume>283</volume><fpage>E937</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">12376320</pub-id></citation></ref><ref id="pone.0004254-Carskadon1"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carskadon</surname><given-names>MA</given-names></name><name><surname>Acebo</surname><given-names>C</given-names></name><name><surname>Jenni</surname><given-names>OG</given-names></name></person-group><year>2004</year><article-title>Regulation of adolescent sleep: implications for behavior.</article-title><source>Ann N Y Acad Sci</source><volume>1021</volume><fpage>276</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">15251897</pub-id></citation></ref><ref id="pone.0004254-Schneider1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>HJ</given-names></name><name><surname>Pagotto</surname><given-names>U</given-names></name><name><surname>Stalla</surname><given-names>GK</given-names></name></person-group><year>2003</year><article-title>Central effects of the somatotropic system.</article-title><source>Eur J Endocrinol</source><volume>149</volume><fpage>377</fpage><lpage>392</lpage><pub-id pub-id-type="pmid">14585082</pub-id></citation></ref><ref id="pone.0004254-Obal1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Obal</surname><given-names>F</given-names><suffix>Jr</suffix></name><name><surname>Krueger</surname><given-names>JM</given-names></name></person-group><year>2001</year><article-title>The somatotropic axis and sleep.</article-title><source>Rev Neurol (Paris)</source><volume>157</volume><fpage>S12</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">11924022</pub-id></citation></ref><ref id="pone.0004254-Mai1"><label>37</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>JK</given-names></name><name><surname>Assheuer</surname><given-names>J</given-names></name><name><surname>Paxinos</surname><given-names>G</given-names></name></person-group><year>1997</year><source>Atlas of the human brain</source><publisher-loc>San Diego</publisher-loc><publisher-name>Academic Press</publisher-name></citation></ref><ref id="pone.0004254-Paxinos1"><label>38</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Paxinos</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name></person-group><year>1995</year><source>Atlas of the human brainstem</source><publisher-loc>San Diego</publisher-loc><publisher-name>Academic Press</publisher-name></citation></ref><ref id="pone.0004254-Tomita1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomita</surname><given-names>H</given-names></name><name><surname>Vawter</surname><given-names>MP</given-names></name><name><surname>Walsh</surname><given-names>DM</given-names></name><name><surname>Evans</surname><given-names>SJ</given-names></name><name><surname>Choudary</surname><given-names>PV</given-names></name><etal/></person-group><year>2004</year><article-title>Effect of agonal and postmortem factors on gene expression profile: quality control in microarray analyses of postmortem human brain.</article-title><source>Biol Psychiatry</source><volume>55</volume><fpage>346</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">14960286</pub-id></citation></ref><ref id="pone.0004254-Vandesompele1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vandesompele</surname><given-names>J</given-names></name><name><surname>De Preter</surname><given-names>K</given-names></name><name><surname>Pattyn</surname><given-names>F</given-names></name><name><surname>Poppe</surname><given-names>B</given-names></name><name><surname>Van Roy</surname><given-names>N</given-names></name><etal/></person-group><year>2002</year><article-title>Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.</article-title><source>Genome Biol</source><volume>3</volume><fpage>RESEARCH0034</fpage><pub-id pub-id-type="pmid">12184808</pub-id></citation></ref><ref id="pone.0004254-Broberger1"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Broberger</surname><given-names>C</given-names></name><name><surname>De Lecea</surname><given-names>L</given-names></name><name><surname>Sutcliffe</surname><given-names>JG</given-names></name><name><surname>Hokfelt</surname><given-names>T</given-names></name></person-group><year>1998</year><article-title>Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems.</article-title><source>J Comp Neurol</source><volume>402</volume><fpage>460</fpage><lpage>474</lpage><pub-id pub-id-type="pmid">9862321</pub-id></citation></ref><ref id="pone.0004254-Hakansson1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hakansson</surname><given-names>M</given-names></name><name><surname>de Lecea</surname><given-names>L</given-names></name><name><surname>Sutcliffe</surname><given-names>JG</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Meister</surname><given-names>B</given-names></name></person-group><year>1999</year><article-title>Leptin receptor- and STAT3-immunoreactivities in hypocretin/orexin neurones of the lateral hypothalamus.</article-title><source>J Neuroendocrinol</source><volume>11</volume><fpage>653</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">10447804</pub-id></citation></ref><ref id="pone.0004254-Taheri1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>The development of monoclonal antibodies against hypocretin-1 (orexin A).</article-title><source>In Sleep</source><fpage>A243</fpage></citation></ref><ref id="pone.0004254-Lin2"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Wisor</surname><given-names>J</given-names></name><name><surname>Shiba</surname><given-names>T</given-names></name><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Yanai</surname><given-names>K</given-names></name><etal/></person-group><year>2002</year><article-title>Measurement of hypocretin/orexin content in the mouse brain using an enzyme immunoassay: the effect of circadian time, age and genetic background.</article-title><source>Peptides</source><volume>23</volume><fpage>2203</fpage><lpage>2211</lpage><pub-id pub-id-type="pmid">12535700</pub-id></citation></ref><ref id="pone.0004254-Zhang1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zeitzer</surname><given-names>JM</given-names></name><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>S</given-names></name><name><surname>Mignot</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>Sleep/wake fragmentation disrupts metabolism in a mouse model of narcolepsy.</article-title><source>J Physiol</source><volume>581</volume><fpage>649</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">17379635</pub-id></citation></ref><ref id="pone.0004254-Sakurai2"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Moriguchi</surname><given-names>T</given-names></name><name><surname>Furuya</surname><given-names>K</given-names></name><name><surname>Kajiwara</surname><given-names>N</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><etal/></person-group><year>1999</year><article-title>Structure and function of human prepro-orexin gene.</article-title><source>J Biol Chem</source><volume>274</volume><fpage>17771</fpage><lpage>17776</lpage><pub-id pub-id-type="pmid">10364220</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by NIH-MH073435 to E. Mignot and by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid for Scientific Research 19390310, 1739034 and Science Research on Priority Areas &#x0201c;Comprehensive Genomics&#x0201d; and in part by Uehara Memorial Foundation to M. Honda. E. Mignot (Investigator) is funded by the Howard Hughes Medical Institute.</p></fn></fn-group></back></article> 